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Rethinking FDA Regulation of Complex Products
Philip E. Alford, PhD
On the outside, modern pharmaceuticals may look much the
same as they have for decades—colorful two-tone capsules,
nondescript tablets, and mysterious names—but inside each
dose is an increasingly complex arrangement of components.
Today, many drugs derive their therapeutic properties not only
from the presence of a single pharmacologically-active
compound, but from the interplay and assembly of multiple
active components.1 In some cases, the resulting product is so
complex that current science is not capable of explaining all
aspects that impart therapeutic effects.2 Even when these
products consist solely of non-biological molecules, they can
nonetheless bear a closer resemblance to biological and
mechanical products than to conventional small molecule
pharmaceuticals.3 Other complex modern products include

1. See JILL B. CONNER ET AL., Copaxone® in the Era of Biosimilars and
Nanosimilars, in HANDBOOK OF CLINICAL NANOMEDICINE: NANOPARTICLES,
IMAGING, THERAPY, AND CLINICAL APPLICATIONS 790 (2016); Markham C.
Luke, Director, Division of Therapeutic Performance, U.S. Food & Drug Admin.,
Address at Generic + Biosimilar Medicines Conference (Nov. 6, 2019),
https://accessiblemeds.org/sites/default/files/2019-11/Complex-ProductWorkshop-GRxBiosims.pdf; CROMMELIN ET AL., NON-BIOLOGICAL COMPLEX
DRUGS THE SCIENCE AND THE REGULATORY LANDSCAPE 1–8 (2015); Xiaohui
Jiang, Deputy Director, Division of Therapeutic Performance, Address at
Demonstrating Equivalence of Generic Complex Drug Substances and
Formulations (Oct. 6, 2017), https://www.fda.gov/media/108937/download;
OFFICE
OF
GENERIC
DRUGS,
2019
ANNUAL
REPORT
(2020),
https://www.fda.gov/media/135329/download; U.S. FOOD & DRUG AMIN.,
GENERIC DRUG USER FEE AMENDMENTS (GDUFA) SCIENCE AND RESEARCH
PRIORITY
INITIATIVES
FOR
FISCAL
YEAR
2020
(2019),
https://www.fda.gov/media/132370/download; see also Vinod Shah, NonBiological Complex Drugs, Non-Biological Complex Drugs (NBCD) Working
Group, Address at Complex Medicines: Science, Regulation, and Accelerating
Development (May 13, 2019), https://www.fda.gov/media/125176/download.
2. See Shah, supra note 1; Teva Neuroscience, Inc. Citizen Petition, No.
FDA-2015-P-1050-0001 (U.S. Food & Drug Admin. Apr. 1, 2015). See also
CROMMELIN ET AL., supra note 1 at 1–8.
3. See Shah, supra note 1.
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combinations of drugs and devices, in which the functioning of
the drug is linked to the output of a diagnostic test, mechanical
delivery system, computer, or other device.4 Medicine that is
personalized to each patient or adapts to patient outcomes is on
the horizon.5 Other products incorporate nanotechnology-based
materials, or operate via unfamiliar mechanisms, such that
merely determining the appropriate regulatory framework is
challenging.6 Each of the above could be considered a “Complex
Product.”7 In this Note, the term Complex Products will be used
primarily to refer to non-biologic drugs, devices, and
combination products that involve nanotechnology-based
features8 or operate at the boundary between drug and device.9
Complex Products do not fall neatly into the Food and Drug
Administration (“FDA”)’s existing regulatory schemes for drugs,
devices, biologics, or combinations thereof. The distinction is not
merely semantic: each product classification offers differing
regulatory hurdles and differing mechanisms for permitting
follow-on competition.10 For example, approval of generic non-

4. U.S. FOOD & DRUG AMIN., USER INTERFACE CONSIDERATIONS FOR
DRUG-DEVICE COMBINATION PRODUCTS SUBMITTED IN AN ANDA,
http://pqri.org/wp-content/uploads/2017/02/6-PQRI-Chan.pdf (last visited Apr.
16, 2020).
5. See id.; Press Release, U.S. Food & Drug Amin., FDA Approves Pill with
Sensor that Digitally Tracks if Patients Have Ingested their Medication, U.S.
FOOD & DRUG ADMIN. (Nov. 13, 2017), https://www.fda.gov/news-events/pressannouncements/fda-approves-pill-sensor-digitally-tracks-if-patients-haveingested-their-medication (describing Abilify MyCite as a schizophrenia drug
that contains a sensor in each pill that records that the medication was taken
and reports to a wearable patch, embedded in the pill, that records that the
medication was taken).
6. See C. Lee Ventola, Progress in Nanomedicine: Approved and
Investigational Nanodrugs, 42 PHARMACY & THERAPEUTICS 723, 742–55 (2017),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720487/.
7. See U.S. FOOD & DRUG ADMIN., GENERIC DRUG PERFORMANCE GOALS
AND
PROCEDURES
FISCAL
YEARS
2018–2022
(2016),
https://www.fda.gov/media/101052/download (defining “Complex Product”).
8. Id.
9. See discussion infra Section I(C)(ii).
10. In this note, the term “follow-on” refers to products or manufacturers
seeking to replicate the success of a prior-approved product of another. This
term is used rather than “generic,” which refers specifically to 510(k)-type drugs
but without intending to specifically refer to generics. Examples of follow-on
products are generics, biosimilars, and 510k devices. Follow-on companies, e.g.,
generic manufacturers, represent subsequent market entrants that serve as
competition to bring prices down. The initial innovator is commonly referred to
as brand side, pioneer, or innovator.
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biologic complex drugs (NBCDs) proceeds via an abbreviated
new drug application (ANDA) pathway. This pathway typically
requires an identical active ingredient and equivalent
bioavailability and bioequivalence, yet NBCDs often cannot be
fully characterized in terms of active ingredient and
bioavailability.11 Devices containing nanomaterials can be
approved for market and serve as predicates upon which further
approvals can be based, but minor variations in nanomaterials
can result in significant changes in biological risk. Complex
drug-device combinations can tie the functioning of a drug to the
operation of a device, which can confound models for predicting
bioequivalence.12
The U.S. Government Accountability Office (GAO) has
urged regulatory development in the area of Complex
Products,13 but the FDA has indicated that regulatory progress
is presently limited by current science.14 Congress has

11. See e.g., Teva Neuroscience, Inc. Citizen Petition, No. FDA-2015-P1050-0001 (Apr. 1, 2015), FDA-2014-P-0933-0001 (July 2, 2014); see also Teva
Pharmaceuticals USA v. Sandoz, Inc., 573 U.S. 318 (2015); see also FDA
Approves a Generic for Teva’s Copaxone, Bringing Longstanding Regulatory
Battles Near an End, PHARMACEUTICAL COMMERCE (Apr. 16, 2015),
http://www.pharmaceuticalcommerce.com/latest-news/fda-approves-a-genericfor-tevas-copaxone-bringing-longstanding-regulatory-battles-near-an-end/.
12. See, e.g., IKARIA, INC. (Kleinfeld, Kaplan, and Becker, LLP) - Citizen
Petition,
https://www.regulations.gov/contentStreamer?documentId=FDA2013-P-0070-0001&attachmentNumber=1&contentType=pdf. (objecting to
510k clearance for a follow-on nitric oxide delivery system; citizen petitions are
often submitted to the FDA when an interested party is concerned that a followon product will be approved despite differences in equivalency).
13. U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-18-80, GENERIC DRUGS:
FDA SHOULD MAKE PUBLIC ITS PLANS TO ISSUE AND REVISED GUIDANCE ON
NONBIOLOGICAL
COMPLEX
DRUGS
(2017),
https://www.gao.gov/assets/690/689047.pdf; U.S. GOV’T ACCOUNTABILITY
OFFICE, GAO-17-452, GENERIC DRUG USER FEES: APPLICATION REVIEW TIMES
DECLINED, BUT FDA SHOULD DEVELOP A PLAN FOR ADMINISTERING ITS
UNOBLIGATED USER FEES (2017), https://www.gao.gov/assets/690/684950.pdf
(noting that generic competition around complex drugs poses unique scientific
and regulatory challenges and should be a primary focus area for regulatory
development).
14. See Upcoming Product-Specific Guidances for Complex Generic Drug
Product
Development,
U.S.
FOOD
&
DRUG
ADMIN.,
https://www.fda.gov/drugs/guidances-drugs/upcoming-product-specific
-guidances-complex-generic-drug-product-development (last updated Nov. 21,
2019) (listing complex products for which the FDA plans to provide additional
product specific guidances). Such guidances are in line with the FDA’s GDUFA
II commitment letter and Congress’s mandate under FDAMA. See e.g., U.S.
FOOD & DRUG ADMIN., supra note 7; see also FDA Reauthorization Act of 2017,
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repeatedly pushed for the FDA to better facilitate approval of
follow-on competition for Complex Products.15 In response, the
FDA has focused on new efforts to bring complex generic
products to market. By 2020, Complex Products accounted for
eleven percent of prior-year generic approvals and more than
fifty percent of all prior-year product specific guidances (PSGs).16
This Note will discuss challenges surrounding Complex
Products, particularly where such products do not find a suitable
place in existing regulatory pathways. In part one, this Note will
provide an overview of Complex Products, discuss the existing
regulatory pathways for drugs, biologics, and devices, and
explain how the FDA determines which regulatory framework
applies to a given product. In part two, this Note will examine
problems with the FDA’s current approach to handling Complex
Products within its regulatory framework. In part three, this
Note suggests rethinking the chemistry-based requirements
written into the Food, Drug & Cosmetic Act (“FD&C Act”) and
adjusting the delineations between product classifications.
Lastly, this Note proposes that Congress provide an incentive to
innovators to disclose data, tolerances, and know-how that will
lower overall costs for development in the industry and improve
scientific
understanding
of
Complex
Products
and
nanotechnology in medicine.

Pub. L. No. 115-52, 131 Stat. 1005 (2017) (providing provisions to facilitate
generic drug approval, including generic complex products).
15. See January 17, 2020 Letter to FDA Commissioner Stephen Hahn,
Committee on Energy and Commerce, House of Representatives; see also
GENERIC DRUG USER FEE AMENDMENTS OF 2017, TITLE III, FDA
REAUTHORIZATION ACT OF 2017 PUB. L. 115-52, §§ 301-307, 131 STAT. 1005,
1020-28 (2017) (providing provisions to facilitate generic drug approval,
including of Complex Products); GENERIC COMPLEX DRUGS SAFETY AND
EFFECTIVENESS FOR PATIENTS ACT OF 2015, H.R. 1576, 114TH CONG. (2015)
(discussing a failed bill proposing to require a study by the Government
Accountability Office (GAO) to assess the Food and Drug Administration’s
current regulatory pathway for reviewing generic versions of nonbiologic
complex drug products).
16. OFFICE OF GENERIC DRUGS, 2019 ANNUAL REPORT (2020),
https://www.fda.gov/media/135329/download.
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I. BACKGROUND
A. COMPLEX PRODUCTS AND NANOTECHNOLOGY-BASED
PRODUCTS
FDA efforts are increasingly focused on Complex Products,
which can be more difficult to develop due to technological and
regulatory uncertainty.17 In 2019, the FDA approved more than
a hundred generic forms of Complex Products (eleven percent of
total generic approvals in 2019) and more than half of the FDA’s
product specific guidances (PSGs) were for Complex Products.18
Starting in 2020, the FDA began providing a forward-looking list
of the product specific guidances it plans to release for generic
Complex Products. This focus is largely a response to
congressional pressure to increase competition and reduce prices
of Complex Products.19 However, as discussed below, the FDA is
still exploring a precise definition for Complex Products.
The FDA first defined Complex Products in response to
congressional concern that the existing ANDA-type generic
pathway was not suitable for complex modern pharmaceuticals.
The FDA initially defined Complex Products as follows:
1. Products with complex active ingredients (e.g., peptides,
polymeric compounds, complex mixtures of APIs, naturally sourced
ingredients); complex formulations (e.g., liposomes, colloids); complex
routes of delivery (e.g., locally acting drugs such as dermatological
products and complex ophthalmological products and optic dosage
forms that are formulated as suspensions, emulsions or gels) or
complex dosage forms (e.g., transdermals, metered dose inhalers,
extended release injectables);
2. Complex drug-device combination products (e.g., auto injectors,
metered dose inhalers); and
3. Other products where complexity or uncertainty concerning the
approval pathway or possible alternative approach would benefit from
early scientific engagement. 20

Subsequent characterizations of Complex Products by the
Division of Therapeutic Performance and Office of
Pharmaceutical Quality have provided the following taxonomy:
17. Id.
18. Id.
19. See GENERIC DRUG USER FEE AMENDMENTS OF 2017, TITLE III, FDA
REAUTHORIZATION ACT OF 2017 PUB. L. 115-52, §§ 301-307, 131 STAT. 1005,
1020-28 (2017) (providing provisions to facilitate generic drug approval,
including the approval of Complex Products).
20. See U.S. FOOD & DRUG ADMIN., supra note 7 (providing a definition for
Complex Product).
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complex active ingredients (e.g., mixtures of APIs, polymeric
compounds, synthetic peptides, and naturally sourced
ingredients), complex formulations (e.g., liposomes, suspensions,
gels, emulsions and other colloids), complex routes of delivery
(e.g., complex ophthalmic products, locally-acting drugs
including dermatologic products, and inhaled products), complex
dosage forms (e.g., long acting injectables, implantables,
transdermals, aerosols), complex drug-device combinations (e.g.,
dry powder inhalers, metered dose inhalers, nasal sprays,
autoinjectors), and other Complex Products (e.g., abuse
deterrent opioid formulations).21
The 2019 Annual Report from the Office of Generic Drugs
and the Generic Drug User Fee Amendments (GDUFA)
Regulatory Science Priority Initiatives for Fiscal Year 2020
further organizes such Complex Products into three groups:
“Complex active ingredients, formulations, and dosage forms”;
“Complex routes of delivery”; and “Complex drug-device
combinations.”22
In each case, the FDA has found it easiest to define Complex
Products by way of examples. Table 1, below, provides examples
of Complex Products referring to the above three groups. The
products in group “A” present challenges related to
characterization and distribution of molecular and nanoscale
features.23 Group “B” products involve challenges related to
pharmacokinetics (describing absorption and distribution
through the body) and bioequivalence (showing no difference in
therapeutic effect compared to a reference).24 Group “C” products
are combination products, but for which the interplay of drug
and device is sufficiently complex that drug effects are not
readily modeled or predicted based on the functioning of the
device, e.g., due to ergonomics, usability, and human-factor

21. See Jiang, supra note 1; See also Katherine Tyner, Associate Director
for Science, Office of Pharmaceutical Quality, An Overview of Complex Drug
Substances
and
Complex
Formulations—A
Quality
Perspective,
https://pqri.org/wp-content/uploads/2019/04/2-TynerPQRI.pdf (last accessed
Apr. 18, 2020).
22. See OFFICE OF GENERIC DRUGS, 2019 ANNUAL REPORT (2020),
https://www.fda.gov/media/135329/download; GENERIC DRUG USER FEE
AMENDMENTS (GDUFA) SCIENCE AND RESEARCH PRIORITY INITIATIVES FOR
FISCAL YEAR 2020 (2020), https://www.fda.gov/media/132370/download.
23. See OFFICE OF GENERIC DRUGS, 2019 ANNUAL REPORT, supra note 22.
24. Id.
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effects.25 In some contexts, Complex Products have been
described as nanomedicine.26 Indeed, the challenges in
classifying Complex Products reflect more general challenges in
describing the application of nanotechnology to non-biologic
drugs and devices.27
Table 1. Examples of Complex Products.
Brand
Product

Renvela®
28

Doxil®29

Generic
Name

Description

Indication

Sevelamer
carbonate

Mixture of
linear,
branched and
crosslinked
polymer
structures

Liposomal
doxorubicin

Chemotherapy
drug
encapsulated
in a nano-scale
lipid bilayer
vesicle

Phosphorus
control in
patients with
chronic kidney
disease on
dialysis
Ovarian
cancer, AIDSrelated
Kaposi’s
sarcoma, and
multiple
myeloma

Author’s
Suggested
Complex
Product
Group

A

A and B

25. Id.
26. Daan J. A. Crommelin & Jon S. B. de Vlieger, Non-Biological Complex
Drugs, in AAPS ADVANCES IN THE PHARMACEUTICAL SCIENCES SERIES 20, 1–2
(2015).
27. Id.
28. See
Renvela
Label,
U.S.
FOOD
&
DRUG
ADMIN.,
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022127s011lbl.pdf
(last accessed Apr. 18, 2020).
29. See
Doxil
Label,
U.S.
FOOD
&
DRUG
ADMIN.,
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050718s029lbl.pdf
(last accessed Apr. 18, 2020).
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®30

MINN. J. L. SCI. & TECH.
Tobramycin
and
dexamethaso
ne
ophthalmic
suspension

Copaxone
®31

Glatiramer
acetate
injection

Risperdal
®
Consta®32

Risperidone
long acting
injection

Voltaren
® Gel33

Diclofenac
sodium
topical gel

A suspension
of topical
antibiotic and
corticosteroid
Polymeric
mixture of
peptide
fragments in a
pre-filled
autoinjector
Risperidone
impregnated
in microscale
poly lactic-coglycolic acid
microspheres
Nonsteroidal
antiinflammatory
drug in topical
formulation

[Vol. 21:2

Superficial
bacterial
ocular
infection

A and B

Multiple
sclerosis

A and C

Schizophrenia

A and C

Osteoarthritis
pain at joints
amenable to
topical
treatment

B

30. See
Tobradex
Label,
U.S.
FOOD
&
DRUG
ADMIN.,
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050818lbl.pdf (last
accessed Apr. 18, 2020).
31. See
Copaxone
Label,
U.S.
FOOD
&
DRUG
ADMIN.,
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020622s102lbl.pdf
(last accessed Apr. 18, 2020).
32. See Risperdal Consta Label, U.S. FOOD & DRUG ADMIN.,
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021346_s31_s35_s
38_s39lbl.pdf (last accessed Apr. 18, 2020).
33. See Voltaren Gel Label, U.S. FOOD & DRUG ADMIN.,
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/0221
22s006lbl.pdf (last accessed Apr. 18, 2020); see also Certara’s Simcyp PBPK
M&S Technology Achieves First FDA Virtual Bioequivalence Approval for
‘Complex’
Generic
Drug,
CERTARA
(June
12,
2019),
https://www.certara.com/pressreleases/certaras-simcyp-pbpk-modeling-andsimulation-technology-achieves-first-fda-virtual-bioequivalence-approval-forcomplex-generic-drug/?.
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EpiPen®34

Epinephrine
injection

ProAir®
HFA35

Albuterol
sulfate
inhalation
aerosol

Advair
Diskus®36

Fluticasone
and
salmeterol
oral inhaler

NuvaRing
®37

Etonogestrel
and
ethinyl
estradiol
vaginal ring

Epinephrine
formulation in
pre-filled
autoinjector
Albuterol
sulfate in a
metered dose
inhaler
Mixture of a
corticosteroid
and beta2adrenergic
bronchodilator
in a metered
dose inhaler
Polymeric
vaginal ring
infused with
hormones

Emergency
treatment of
anaphylactic
reactions

C

Bronchospasm

B and C

Asthma, COPD

A, B, and C

Contraceptive

A, B, and C

This Note suggests a more specific working definition for
Complex Products, loosely based around the characteristics of
Groups A, B, and C.38
Lawmakers have focused on non-biological complex drug
products because the generic-type pathway for follow-on drugs
requires certain technical showings that are challenging for

34. See EPIPEN® Label, U.S. FOOD & DRUG ADMIN., U.S. FOOD & DRUG
ADMIN.,
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019430s053lbl.pdf
(last accessed Apr. 18, 2020).
35. See ProAir HFA Label, U.S. FOOD & DRUG ADMIN.,
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021457s036lbl.pdf
(last accessed Apr. 18, 2020).
36. See Advair Diskus Label, U.S. FOOD & DRUG ADMIN.,
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021077s029lbl.pdf
(last accessed Apr. 18, 2020).
37. See
NuvaRing
Label,
U.S.
FOOD
&
DRUG
ADMIN.,
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021187s012lbl.pdf
(last accessed Apr. 18, 2020).
38. See infra Section II.
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Complex Products.39 In contrast, Complex Products that are
regulated as devices and biologics allow follow-on competition to
proceed via the more-flexible PMA or biosimilar pathways.40
Although Complex Products are not synonymous with nonbiological products, this Note focuses on the drug-device
distinction and unique challenges posed by non-biological
Complex Products.41
i.

Non-Biological Complex Drugs (NBCDs)

Non-Biological Complex Drugs (NBCDs) likely represent
the most important subset of Complex Products, due to the
unique regulatory challenges surrounding approval of complex
generic equivalents.42 An industry-supported working group has
described NBCDs as drugs in which the active substance is not
a single, discrete molecular structure, but instead derives its
activity from a particular mixture or nanoscale arrangement of
components.43 In some cases, it may not be feasible to fully
characterize or describe the active substance by present
analytical methods and subtle variations can impart dramatic
changes in functioning.44 Arguably, the defining aspect of
NBCDs is that they “cannot be fully isolated, quantitated,
characterized or described by physicochemical analytical
means.”45 Moreover, the biological and therapeutic activity of
NBCDs is often highly dependent on its manufacturing
39. See U.S. FOOD & DRUG ADMIN., supra note 7 (providing a rationale for
its pre-ANDA program and enhanced pathway for Complex Products and
providing a definition for combination products focused around drug and device
features).
40. See infra Sections I(E)(ii) and I(E)(iii).
41. See infra Sections I(C) and II.
42. See Equivalence of Complex Drug Products, GENERICS AND
BIOSIMILARS INITIATIVE (Apr. 14, 2017), http://www.gabionline.net/NonBiological-Complex-Drugs/Reports/Equivalence-of-complex-drug-products
(summarizing that showing therapeutic equivalence of generic complex drugs
has unique challenges).
43. See Shah, supra note 1 (stating NBCDs are an “active substance that is
not homo-molecular but contains different (closely related, often nanoparticulate) structures”).
44. See Víctor R. Campos-García et al., Process Signatures in Glatiramer
Acetate Synthesis: Structural and Functional Relationships, 7 SCIENTIFIC REP.
12525, at 1–7 (Sept. 21, 2017), https://www.nature.com/articles/s41598-01712416-1 (showing that subtle changes in epitope abundance in glatiramer
acetate results in substantial changes in therapeutic function); see also Shah,
supra note 41.
45. Campos-García et al., supra note 44 at 1.
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process.46 NBCDs have been described as non-biologic products
that have complexity approaching that of biological products.47
NBCDs are a structurally and functionally diverse family of
medical products, including: (1) polymeric micelles; (2)
liposomes; (3) glatiramoids; (4) iron carbohydrate complexes; (5)
drug nanocrystals; (6) low molecular weight heparins; and (7)
albumin-bound drugs.48 For example, glatiramoids, such as
Copaxone® and Glatopa®, comprise a mixture of polymer
building blocks that self-assemble in the human body to form
biologically active structures.49 Liposome-based drugs, such as
Doxil®, involve tiny vesicles that encapsulate a potent
therapeutic and carry it to a desired part of the human body. 50
As another example, Abraxane® involves nanocrystals of
paclitaxel bound to albumin, a water-soluble globular protein
obtained from human blood, which serves as a delivery vehicle
for the chemotherapy agent.51 The FDA has created a working
group dedicated to investigating regulatory challenges
associated with NBCDs.
ii. Complex Drug-Device Combinations
The FDA does not necessarily deem combination products to
be Complex Products, but certain “complex” drug-device
combinations such as metered dose inhalers and injectors can

46. See Amneal Pharm. LLC v. FDA, 285 F. Supp. 3d 328, 337 (D.D.C. 2018)
(stating that the FDA requires disclosure of “commercial-scale data” for “certain
complex drug products and/or a complex manufacturing process”).
47. See Shah, supra note 1.
48. See Jon S. B. de Vlieger et al., Report of the AAPS Guidance Forum on
the FDA Draft Guidance for Industry: “Drug Products, Including Biological
Products, That Contain Nanomaterials”, 21 AAPS J. 55, 56 (2019),
https://link.springer.com/content/pdf/10.1208/s12248-019-0329-7.pdf (providing
an overview of the complex drug landscape).
49. See J. Y. Song et al., Glatiramer Acetate Persists at the Injection Site
and Draining Lymph Nodes via Electrostatically-Induced Aggregation, 293 J.
CONTROLLED RELEASE 36, 36–47 (2019).
50. See, e.g., Doxil, U.S. FOOD & DRUG ADMIN. 21 (2007),
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050718s029lbl.pdf
(“DOXIL is doxorubicin HCl encapsulated in long-circulating . . . liposomes.
Liposomes are microscopic vesicles composed of a phospholipid bilayer that are
capable of encapsulating active drugs.”).
51. See, e.g., Abraxane, U.S. FOOD & DRUG ADMIN. 1 (2013),
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021660s037lbl.pdf
(“ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles
for injectable suspension) (albumin-bound)”).
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fall within the category.52 Two examples, discussed above, are
the Epi-Pen® epinephrine autoinjector and Advair® metered
dose inhaler.
Combination products seek to address classification
challenges by using a primary mode of action (PMOA) inquiry to
determine whether a given product will progress through the
drug, device, or biologic framework. Yet, such an inquiry does
not remedy the challenges associated with Complex Products,
namely, where present scientific tools and understanding fail to
furnish the information required to transit through the
regulatory framework. Like the drug-device distinction, PMOA
is determined predominantly by the presence of chemical action
and thus chemical action serves as a regulatory gatekeeper even
if the complex product is a combination product. For example, in
the case of an inhaler containing a drug, the drug aspect would
be deemed by the FDA Office of Combination Products to embody
the PMOA while the device aspect would be deemed to serve a
secondary function. However, if a hypothetical competitor
wishes to make a generic inhaler, it is uncertain how similar the
drug and device aspects must be to the referenced product. Most
notably, even an apparently identical copy of a drug and device
may nevertheless result in different bioavailability and
therapeutic function. One reason for this difference is that
complex drug-device combinations are susceptible to user
interface and human factor effects. That is, the look, feel, and
ergonomics of a device can affect how a person administers or
accepts the drug, thus ultimately affecting therapeutic effect.
The device may also affect the structural characteristics of a
drug both before and after administration. These device-based
effects can interplay with drug-based effects in unpredictable
ways, resulting in complexity that makes regulatory approval
uncertain and stymies follow-on competition.
iii. Medical Nanotechnology and Nanodevices
Complex Products also include medical products that
involve nanotechnology, “nanodevices” (drug-like, molecularscale products that do not involve chemical action to achieve
52. See U.S. FOOD & DRUG ADMIN., GDUFA REAUTHORIZATION
PERFORMANCE GOALS AND PROCEDURES FISCAL YEARS 2018-2022, at 25 (2016),
https://www.fda.gov/media/101052/download (providing a definition for
Complex Products that includes “metered dose inhalers” and “extended release
injectables”).
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their therapeutic result, e.g., gold nanoparticles), and other
products for which existing classification or approval pathways
pose a challenge.53 Whether the FDA will deem a given
nanotechnology-based product to be a drug or a device is, again,
determined by whether the intended effect involves “chemical
action.”54 While products involving nanotechnology are not
automatically assigned any special classification, the presence of
nanotechnology can introduce sufficient complexity to render the
FDA’s approval pathway uncertain. Nanotechnology-based
products might thus meet the FDA’s definition of Complex
Products.55
The FDA has taken into account the advent of
nanotechnology-based medicine in its regulatory framework.56
Wisely, the FDA has determined that it will not issue general
regulatory requirements or limitations on the use of

53. Id.
54. See Jordan Paradise, Reassessing Safety for Nanotechnology
Combination Products: What Do Biosimilars Add to Regulatory Challenges for
the FDA?, 56 ST. LOUIS U. L.J. 465, 495 (2012) (citing 21 U.S.C. § 321(h) (2006))
(“[T]he FDCA requires . . . that a device ‘does not achieve its primary intended
purposes through chemical action . . . . ‘”).
55. See FDA’s Approach to Regulation of Nanotechnology Products, U.S.
FOOD & DRUG ADMIN., https://www.fda.gov/science-research/nanotechnologyprograms-fda/fdas-approach-regulation-nanotechnology-products (last updated
Mar. 23, 2018) (“[The] FDA has long encountered the combination of promise,
risk, and uncertainty that accompanies emerging technologies. Nanotechnology
is not unique in this regard.”); see also MARK DUVALL, FDA REGULATION OF
NANOTECHNOLOGY 101 (2012) (“In light of the potential uncertainty
surrounding the debate, it may be helpful for FDA to issue guidance on the
subject [of nanotechnology-based devices].”). See generally Paradise, supra note
50.
56. See U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: DRUG
PRODUCTS,
INCLUDING
BIOLOGICAL
PRODUCTS,
THAT
CONTAIN
NANOMATERIALS
(2017),
https://www.fda.gov/media/109910/download
(proposing, in a Draft Guidance document for comment purposes, a “risk-based”
approach to products containing nano-technology). The document notes, among
other things, that inclusion of nanotechnology “may result in product attributes
that differ from those of products that do not contain such materials,” id. at 1,
“nanomaterial carriers may exhibit inherent biological activity that is not
related to the loaded active ingredient (e.g., immunogenicity) and could also
affect the safety and effectiveness of the drug,” id. at 17, and “[a]ny critical
structural change [by generics] in the multiple components of nanomaterialbased products can influence the bioequivalence, pharmacology, and toxicology
profiles, . . . [therefore] conventional [bioequivalence] studies alone may or may
not be sufficient . . . ,” id. at 21.
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nanotechnology in medicine.57 Still, nanoscale features can
introduce new biological effects that are not otherwise present
in the product and can serve to modulate existing biological
effects.58 The FDA has further recognized that conventional
analytical approaches to evaluating therapeutic products may
not be sufficient when changes are made to nanotechnological
features are altered or introduced.59 Such concerns parallel
those of Complex Products generally. The medical products that
the FDA regulates contain a variety of nanomaterials: for
example, liposomes, micelles, specified nano-scale particle
distributions, nanobubbles, nanocrystals, polymer-based
therapeutics, and complex-based therapeutics—many of the
same features which impart complexity to the products
previously listed in Table 1. 60 Indeed, while nanomaterials are
already commonly used in drugs,61 they can also be used in drugdevice combination products62 and non-drug products as well.63
57. The FDA has instead opted for a scientifically-guided risk-based
approach. See generally id.
58. See id. at 5 (“[T]he interaction of nanomaterials with multiple plasma
proteins . . . may endow nanomaterials with new biological properties.”).
59. Id. See also U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY:
ASSESSING THE EFFECTS OF SIGNIFICANT MANUFACTURING PROCESS CHANGES,
INCLUDING EMERGING TECHNOLOGIES, ON THE SAFETY AND REGULATORY
STATUS OF FOOD INGREDIENTS AND FOOD CONTACT SUBSTANCES, INCLUDING
FOOD
INGREDIENTS
THAT
ARE
COLOR
ADDITIVES
(2014),
https://www.fda.gov/media/115075/download.
60. FDA provides guidance documents for products using nanomaterials in
combination with drugs. See, e.g., U.S. FOOD & DRUG ADMIN., GUIDANCE FOR
INDUSTRY:
LIPOSOME
DRUG
PRODUCTS
(2018),
https://www.fda.gov/media/70837/download (providing guidelines for liposomecontaining drug product applications and recognizing the challenges for both
ANDA and NDA applicants, particularly with respect to determining
bioavailability); See generally Mary C. Till et al., Nanotech Meets the FDA: A
Success Story About the First Nanoparticulate Drugs Approved by the FDA, 2
NANOTECHNOLOGY L. & BUS. 163 (2005) (describing the first wave of nano-sized
drugs that the FDA evaluated).
61. Jordan Paradise has provided a useful review and list of FDA-approved
drugs that involve nanoscale features. See Paradise, supra note 54 at 518–19
(providing a list of both FDA approved drugs and devices that involve
nanotechnology).
62. See U.S. FOOD & DRUG ADMIN., supra note 60 at 10 (providing
guidelines for liposome-containing drug product applications and recognizing
the challenges for both ANDA and NDA applicants, particularly with respect to
determining bioavailability).
63. See U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY:
CONSIDERING WHETHER AN FDA-REGULATED PRODUCT INVOLVES THE
APPLICATION
OF
NANOTECHNOLOGY,
at
6
(2014),
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To determine if a product involves nanotechnology, the FDA
considers whether the “product is engineered to have at least one
external dimension, or an internal or surface structure, in the
nanoscale range (approximately 1 nm to 100 nm)” and if the
“product is engineered to exhibit properties. . . attributable to its
dimension(s), even if these dimensions fall outside the nanoscale
range, up to one micrometer (1,000 nm).” 64 Here, the FDA’s focus
on “engineered” nanoscale features is an attempt to distinguish
from conventionally-occurring and incidental nanoscale features
from those that are intentionally imparted.65
B. OVERVIEW OF FDA REGULATION OF MEDICAL PRODUCTS
The FD&C Act imposes regulatory requirements on
products intended for medical use.66 The FD&C Act requires
that the safety and efficacy of all new drugs be evaluated and
approved by the FDA prior to being introduced into interstate
commerce.67 Since its promulgation in 1938, Congress has
expanded the FDA’s regulatory authority to include additional
classifications of medical products, notably medical devices 68
and drug-like biologics.69
https://www.fda.gov/media/88423/download (providing two factors to consider
in determining if the product involves nanotechnology which may suggest a
need for additional risk assessment and stating “[n]anotechnology is an
emerging technology that can be used in a broad array of FDA-regulated
products, including . . . foods[,] . . . and cosmetics . . . .”).
64. Id. at 6.
65. Id. See U.S. FOOD & DRUG ADMIN., NANOTECHNOLOGY: A REPORT OF
THE U.S. FOOD AND DRUG ADMINISTRATION NANOTECHNOLOGY TASK FORCE 11
(2007), https://www.fda.gov/media/74257/download (“In addition to other
resources, the Task Force also considered the US Government-wide evaluation
of Environmental, Health, and Safety Research Needs for Engineered
Nanoscale
Materials
in
developing
this
discussion
and
these
recommendations.”).
66. See e.g., 21 U.S.C. §§ 331(a) (2011), 331(ll) (2011), 355(a) (2011), 360(k)
(2012) (prohibiting introduction into interstate commerce of misbranded or
unapproved drugs, devices, and biologics).
67. See 21 U.S.C. § 355(a) (2011) (“No person shall introduce or deliver for
introduction into interstate commerce any new drug, unless an approval of an
[NDA or ANDA] application. . . .”); Cf. U.S. FOOD & DRUG ADMIN., GUIDANCE
FOR FDA STAFF AND INDUSTRY, MARKETED UNAPPROVED DRUGS – COMPLIANCE
POLICY GUIDE, SEC. 440.100 MARKETED NEW DRUGS WITHOUT APPROVED
NDAS OR ANDAS (2011), https://www.fda.gov/media/71004/download.
68. Medical Device Amendments of 1976, 21 U.S.C. § 301 (1976) (expressly
delegating to FDA the authority to regulate medical devices).
69. The FDA’s authority to regulate biological products derives from both
the Public Health Service Act (“PHS Act”) and the FD&C Act, which were
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The FDA applies distinct regulatory schemes to medical
products depending on whether it classifies the product as a
drug,70 a device,71 a biologic,72 or a combination thereof.73
Jurisdiction over each product is separately designated to
different centers within the FDA.74 Generally, drugs are
designated to the Center for Drug Evaluation and Research
(CDER),75 devices to the Center for Devices and Radiologic
Health (CDRH),76 and biologics to the Center for Biologics
Evaluation and Research (CBER).77 Devices are further
categorized as Class I, Class II, or Class III, based on the extent
that safety and efficacy can be inferred due to the nature of the
device.78 Combination products and other products that do not
fall neatly into existing product classifications are evaluated by
the Office of Combination Products (OCP) and designated to one

subsequently amended and largely harmonized with drug regulations by the
Food and Drug Administration Modernization Act of 1997 (“FDAMA”). See Food
and Drug Administration Modernization Act of 1997, Pub. L. No. 105–115, 111
Stat. 2296 (1997). Oversight over biologics, generally, extends back to the
Biologics Control Act, which became effective in 1903. See also Pure Food and
Drug Act of 1906, Pub. L. No. 59–384, 34 Stat. 768 (1906).
70. 21 U.S.C. § 201(g)(1) (2011) (defining a “drug”).
71. 21 U.S.C. § 201(h) (2011) (defining a “device”).
72. 42 U.S.C. § 262(i) (2011) (defining a “biologic”).
73. 21 C.F.R. § 3.2(e) (2010) (defining a “combination product”).
74. See RFD Jurisdictional Decisions, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/combination-products/jurisdictional-information/rfdjurisdictional-decisions (last updated Feb. 16, 2018).
75. See Capsular Decisions—Products Assigned to CDER, U.S. FOOD &
DRUG ADMIN., https://www.fda.gov/combination-products/rfd-jurisdictionaldecisions/capsular-decisions-products-assigned-cder (last updated Feb. 16,
2018).
76. See Capsular Decisions, supra note 71.
77. See id., many notable exceptions to jurisdiction apply and centers
cooperate and share their expertise where appropriate. See e.g., Transfer of
Therapeutic Biological Products to the Center for Drug Evaluation and
Research, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/combinationproducts/jurisdictional-information/transfer-therapeutic-biological-productscenter-drug-evaluation-and-research (last updated Feb. 16, 2018) (transferring
jurisdiction of therapeutic monoclonal antibodies, immunomodulators, and
growth factors from CBER to CDER); see also Intercenter Agreement Between
the Center for Biologics Evaluation and Research and the Center for Devices and
Radiological
Health,
U.S.
FOOD
&
DRUG
ADMIN.,
https://www.fda.gov/combination-products/jurisdictionalinformation/intercenter-agreement-between-center-biologics-evaluation-andresearch-and-center-devices-and (last updated Feb. 16, 2018) (transferring
jurisdiction of in vitro blood diagnostics to CBER from CDRH).
78. 21 U.S.C. § 360c (2012).

2020]

COMPLEX PRODUCTS

493

of the centers, i.e., CDER, CDRH, or CBER, which have primary
jurisdiction for premarket review and regulatory life of the
product.79
C. CLASSIFICATION OF MEDICAL PRODUCTS
i.

Is it a Drug, Device, or Biologic?

Product classification determines the structure of the FDA’s
premarket review and regulatory pathways for follow-on
competition. The scope and burden of premarket review varies
enormously between product classifications: drug pre-clinical
investigations, clinical trials, and regulatory approval take an
average of twelve years and over $350 million80 while the most
burdensome form of device clinical investigation and approval
averages 4.5 years and $75 million.81 Further, for medical
products that make it to market, the strength and duration of
regulatory exclusivity differs based on the product’s
classification.82
The FD&C Act defines drugs to include “articles intended
for use in the diagnosis, cure, mitigation, treatment, or
prevention of disease in man or other animals” and “articles
(other than food) intended to affect the structure or any function
of the body of man or other animals” as well as articles listed in
certain pharmacopeial compendia and components of any of the
same.83

79. See Jurisdictional Information, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/combination-products/classification-and-jurisdictionalinformation (last updated Apr. 9, 2020).
80. Matthew Herper, The Cost of Creating a New Drug Now $5 Billion,
Pushing Big Pharma to Change, FORBES PHARMA & HEALTHCARE (Aug. 11,
2013),
https://www.forbes.com/sites/matthewherper/2013/08/11/how-thestaggering-cost-of-inventing-new-drugs-is-shaping-the-future-ofmedicine/#7753cc096bfc.
81. Brian Buntz, FDA Planning Faster PMA Pathway for Some Products,
MEDICAL DEVICE AND DIAGNOSTIC INDUSTRY (Jan. 31, 2014),
https://www.mddionline.com/fda-planning-faster-pma-pathway-some-products.
82. See e.g., 21 C.F.R. §§ 314.108 (2012), 316.31 (2011), & 316.34 (2004); see
also FD&C Act, 21 U.S.C 9 §§ 505A, 505E, & 505(j)(5)(B)(iv) (2012) (providing
various regulatory extensions). Compare 21 U.S.C. § 355(b) (2011), and 21
U.S.C. § 360(k) (2012), with 42 USC § 262(l) (2011) (providing the ANDA process
for a generic drug, 510(k) process for a substantially equivalent device, and
process for a biosimilar).
83. 21 U.S.C. § 321(g)(1) (2011) (defining a “drug”).
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Within the FD&C Act, devices are defined as a subset of
article, specifically “an instrument, apparatus, implement,
machine, contrivance, implant, in vitro reagent, or other similar
or related article.”84 The statutory definition of a device is
further categorized according to intended use, similar to that for
a drug, but with an important limitation. Mirroring the
language used to define drugs, the FD&C Act defines devices as
“intended for use in the diagnosis of disease or other conditions,
or in the cure, mitigation, treatment, or prevention of disease, in
man or other animals,” or “intended to affect the structure or any
function of the body of man or other animals . . . .” 85 However, in
the FD&C Act, Congress expressly required that a device “not
achieve its primary intended purposes through chemical action
within or on the body of man or other animals and which is not
dependent upon being metabolized for the achievement of its
primary intended purposes . . . .”86
In the FD & C Act, a product is classified as a biologic if it
is:
[A] virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood
component or derivative, allergenic product, protein (except any
chemically synthesized polypeptide), or analogous product, or
arsphenamine or derivative of arsphenamine (or any other trivalent
organic arsenic compound), applicable to the prevention, treatment, or
cure of a disease or condition of human beings.87

That is, biologics are defined by origin, while drugs and
devices are defined by intended use.
Although the FDA relies on these statutory definitions to
determine how to classify a given product, the agency has
historically interpreted these definitions broadly so as to
preserve its authority to regulate.88 For example, the FDA

84. 21 U.S.C. § 321(h) (2011) (defining a “device”).
85. Id.
86. Id.
87. 42 U.S.C. § 262(i) (2011) (defining a “biologic”).
88. See United States v. Bacto-Unidisk, 394 U.S. 784, 800 (1969) (deferring
to the FDA’s authority to interpret an antibiotic diagnostic apparatus as a drug
rather than a device). Even after subsequent amendments provided express
distinctions between drugs and devices, the FDA retained its willingness to use
discretion to classify a product according to the interest of the public health. See
U.S. FOOD & DRUG ADMIN., CLASSIFICATION OF PRODUCTS AS DRUGS AND
DEVICES AND ADDITIONAL PRODUCT CLASSIFICATION ISSUES (2017),
https://www.fda.gov/media/80384/download. However, at least one district
court has suggested that the FDA’s position is not tenable. See Bracco
Diagnostics Inc v. Shalala, 963 F. Supp. 20, 28, 31 (D.D.C. 1997).
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presently considers that, conceptually, all medical products
meet the definition of a drug.89 Indeed, the definition of a device
can be interpreted as defining a subset of the drug definition;
specifically, a subset having the limitation that they do not
achieve their primary intended purposes via chemical action, or
metabolism, within or on the body.90 The genera of products
listed in the biologics definition can be likewise interpreted as
another subset of drugs.91 Products that meet the definition of
both a drug and a biologic are classified as a biologic, while
products that meet the definition of both a drug and a device are
classified as a device.92 Whether a product is a device rather than
a drug or biologic will hinge on whether the product achieves its
primary intended purposes through “chemical action” within or
on the body.93 Because neither drugs nor biologics include food,
the provision that devices exclude products that achieve their
purpose through metabolism has not been a meaningful
distinction.94

89. See U.S. FOOD & DRUG ADMIN., supra note 88.
90. Congress chose to expressly remove a provision of the FD&C Act that
excluded devices from being drugs. See Safe Medical Devices Act of 1990, Pub.
L. No. 102-629, § 14, 104 Stat. 4511, 4524–25. Still, while still standing safely
outside the rabbit hole of FD&C definitions, it is worth acknowledging that
interpreting all medical products to be drugs invites some absurd consequences.
At the very least, it seems reasonable to expect that products meeting the
definition as device should be permitted passage through the regulatory domain
while classified as devices. See, Genus Med. Tech. v. United States Food & Drug
Admin., Civil Action No. 19-544 (JEB), 2019 U.S. Dist. LEXIS 210397 * 2019
WL 6683777.
91. See U.S. FOOD & DRUG ADMIN., supra note 88; see also Biologics Price
Competition and Innovation Act of 2009, S. 1695, 100th Cong. § 7002(e) (2007).
See also U.S. FOOD & DRUG ADMIN., INTERPRETATION OF THE “DEEMED TO BE A
LICENSE” PROVISION OF THE BIOLOGICS PRICE COMPETITION AND INNOVATION
ACT OF 2009 (2018), https://www.fda.gov/media/119272/download.
92. See U.S. FOOD & DRUG ADMIN., supra note 91.
93. See U.S. FOOD & DRUG ADMIN., supra note 88 (defining chemical
action).
94. See id. (explaining the FDA’s current thinking on chemical action).
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Table 2. Example Classification of Medical Products
Medical Product
An artificial hip implant
Beta blockers, which interact with
beta receptors and block access to the
receptor
A recombinant human granulocyte
colony stimulating factor
An autoinjector configured to provide
metered doses of a synthetic myelin
protein
A complex mixture of polymers that
assemble into a variety of structural
forms that serve to attenuate an
immune response in the human body
A liposome containing a collection of
non-biological molecular components,
including a sensor, a cytotoxin, and a
molecular switch configured to
jettison the cytotoxin upon stimulus
of the sensor
A synthetic tissue embedded with
biologically active components

Classification
Device
Drug
Biologic
Combination

Examples of Complex Products.
Classification is based on
whether the primary intended
purpose is through “chemical
action” within or on the body.

Applicants often seek to have their products classified as a
device rather than a drug or biologic due to the less burdensome
premarket review process afforded to devices.95 Unexpected
classification of a device as a drug can preclude further
development of that product.96 The Office of Combination
95. Id. See also Letter from Jill Hartzel Warner, Assoc. Comm’r for Special
Medical Programs, Food and Drug Admin., to Jeffrey N. Gibbs and Anne K.
Walsh, Attorneys for Prevor (Jan. 13, 2015) (on file with Food and Drug
Administration); Letter from Suzanne O’Shea, Product Jurisdiction Officer,
Food and Drug Admin., to LuAnn Erlich, Senior Dir. of Pharm. and Comput.
Services, Apotex Corp. (Sept. 8, 2003) (on file with Food and Drug
Administration).
96. See Bracco Diagnostics Inc v. Shalala, 963 F. Supp. 20, 28–32
(explaining that small device companies might not be able to afford to bring a
drug to market). Sometimes extensive the consequences of classification justify
repeated and presumably expensive litigation. Cf. Prevor v. FDA, 895 F. Supp.
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Products (OCP) handles the FDA’s classification and jurisdiction
assignments.97 Those pursuing regulatory review can submit
informal inquiries or formal Requests for Designation (RFDs) to
classify the product and identify the center having jurisdiction.
ii. Chemical Action
The FDA recently issued guidance98 regarding how it
applies “chemical action” to distinguish drugs and biologics from
devices.99 Specifically, the FDA has defined chemical action as
follows: “a product exhibits ‘chemical action’ if it interacts at the
molecular level with bodily components (e.g., cells or tissues) to
mediate (including promoting or inhibiting) a bodily response, or
with foreign entities (e.g., organisms or chemicals) so as to alter
that entity’s interaction with the body.”100
Perhaps recognizing the futility of defining “chemical
action” as interactions “at the molecular level,” the FDA has
further provided that:
For purposes of this interpretation, an interaction at the
molecular level occurs through either chemical reaction (i.e.,
formation or breaking of covalent or ionic bonds), intermolecular
forces (e.g., electrostatic interactions), or both. The mere
exchange of non-chemical energy (e.g., electromagnetic or
thermal energy between a product and the body would not
constitute “chemical action.”101
2d 90 (D.D.C. 2012); Prevor v. U.S. Food & Drug Admin., 67 F. Supp. 3d 125
(D.D.C. 2014).
97. See Combination Products, Jurisdictional Information, U.S. FOOD &
DRUG ADMIN., https://www.fda.gov/combination-products/classification-andjurisdictional-information (last accessed Apr. 9, 2020).
98. The FDA publishes its current thinking on various topics by way of
guidance documents. While guidance documents do not have the force of law
and are not binding, they have proven to be an effective means of regulating
industry and developing policy. See Guidances, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/industry/fda-basics-industry/guidances (last updated May
24, 2018) (summarizing the FDA’s use of guidance documents).
99. See U.S. FOOD & DRUG ADMIN., supra note 88 (defining chemical action
and explaining the FDAs current thinking on the same).
100. Id. at 7. For a more reasoned take on chemical action, see, e.g., W.J.
Koolage & R. Hall, Chemical Action: What Is It, and Why Does It Really Matter?,
13 J. NANOPARTICLE RES. 1401, 1401–17 (2011); see also FDA Finalizes Product
Classification Guidance, HYMAN, PHELPS & MCNAMARA PC: FDA L. BLOG (Oct.
3,
2017),
http://www.fdalawblog.net/2017/10/fda-finalizes-productclassification-guidance/; Drug or Device?— FDA Provides More Clarity—or Does
It?, CAMARGO PHARMA: CAMARGO BLOG.
101. U.S. FOOD & DRUG ADMIN., supra note 88, n. 12.
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This is, again, somewhat circular: “chemical action” is
defined as interactions on the “molecular” level, which are
interactions that include “chemical” reactions. However, recent
guidance provides at least one bright line rule: chemical action
is not mere transfer of electromagnetic or thermal energy.102
Pacemakers,
electrocauteries,
cryotherapy,
and
neurostimulation devices are thus firmly on the device side. The
FDA has provided several examples to illustrate products that
do, and do not, achieve their primary purpose through chemical
action.
Table 3. Examples of Medical Products that Illustrate Chemical
Action.103
Does this product achieve
Medical Product
its primary intended purpose
through “chemical action”?
Inert synthetic polymers used
No
to reduce post-operative
tissue adhesions
Acrylate polymer bone filler
No
Topical surgical adhesive
No
Gold nanoparticles that
No
absorb electromagnetic
radiation and radiate thermal
energy damaging nearby
tissue and killing cancer cells
Liquid nitrogen gas used to
No
treat warts
Hydroxocobalamin, which
Yes
binds to cyanide to act as an
antidote
Polymyxin B sulfate, a
Yes
cationic surfactant that is
attracted to and
electrostatically adheres to
the bacterial membrane,
lysing and killing the bacteria

102. Id.
103. Id.
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Magnesium sulfate for
treating magnesium
deficiency
Beta blockers, which interact
with beta receptors and block
access to the receptor
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Yes
Yes

Lastly, the FDA has clarified that the concept of chemical
action relates to the “primary intended purposes” of the device
“as a whole” and thus does not hinge on whether the product
involves any chemical action at all.104 Further, as noted above,
the FDA considers devices to be a subset of drugs, rather than
being a mutually exclusive category. Thus, while a device can be
said to work by means other than chemical action or metabolic
action, the definition for drugs is not restricted with respect to
mode of action.105
D. CLASSIFICATION OF COMBINATION PRODUCTS
i.

Combination Products

When a product comprises two or more separately classified
components, i.e., a mixed pairing of drug, device, or biologic
components, the FDA classifies the product as a combination
product.106 Combination products thus correspond to
drug/device,
biologic/device,
drug/biologic,
or
drug/device/biologic component mixtures. The Federal Code
defines combination products as a product comprising two or
more regulated components:
(1) . . . that are physically, chemically, or otherwise combined or mixed
and produced as a single entity;
(2) . . . packaged together in a single package or . . . ;
(3) . . . packaged separately . . . intended for use only with an approved
individually specified drug, device, or biological product where both are
required to achieve the intended use . . . ; or

104. Id.
105. The FDA’s approach may be challenged by a recent district court
decision in Genus Medical Technologies, which may force the FDA to reconsider
whether at least a contrast agent can be regulated as a drug if it lacks chemical
action, particularly in light of other contrast agents being regulated as devices.
See Genus Medical Tech. v U.S. Food and Drug Admin., Civil Action No. 19-544
(JEB), 2019 U.S. Dist. LEXIS 210397 * | 2019 WL 6683777. Note, also, that
drugs exclude food. See 21 U.S.C. § 321(g)(a) (2011).
106. 21 C.F.R. § 3.2(e) (2005) (defining combination products).

500

MINN. J. L. SCI. & TECH.

[Vol. 21:2

(4) . . . packaged separately . . . for use only with another individually
specified . . . drug, device, or biological product where both are required
to achieve the intended use.107

Combination products are important in the context of
Complex Products since the FDA expressly enumerated complex
drug-device combinations as an example of Complex Products.
ii. Primary Mode of Action
To determine how any given combination product should be
regulated, the FDA first determines the PMOA of the product. 108
Specifically, the FDA will identify the single mode of action that
it expects makes the greatest contribution to the overall
intended therapeutic effect of the product.109 The FDA looks to
determine the “means” by which the product achieves its
intended therapeutic effect. Typically, combination products
exhibit multiple modes of action.110 Unintuitively, this means
that PMOA is based on the action intended, not necessarily the
action that occurs.
Once the PMOA has been identified, the product is classified
based on whether the PMOA corresponds to “[t]he actions
provided by a biological product, a device, and a drug.”111 A
combination product is classified as a biologic if its PMOA “acts
by means of” a product defined as a biologic.112 The combination
product is a device if its PMOA acts by means of a device, but
not if it acts by means of a biological product, or through
chemical action within or on the body, or if it is dependent upon
being metabolized. Lastly, drug classification is a catch all: the
combination product is a drug if it has a PMOA that does not
meet either of their two definitions.113 When looking at device-

107. Id.
108. 21 U.S.C. § 353(g)(d) (2016).
109. 21 U.S.C. § 353(g)(c) (2016).
110. 21 C.F.R. § 3.2(k) (2005).
111. 21 C.F.R. § 3.2(k) (2005).
112. 21 C.F.R. § 3.2(k) (2005). See also 21 U.S.C. § 351(i) (2017) (listing
products that are deemed biologics).
113. Of course, drugs, devices, and biologics do not necessarily function
according to generalized modes of action. Ideally, the FDA prefers to think of
itself as taking a science-based, product-specific approach to regulation, but
Congress has expressly set forth a distinction between drugs, devices, and
biologics. PMOA is simply an unavoidably blunt tool for separating products
into the product categories devised by Congress without any particular
scientific basis.
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drug combination products, classification ultimately depends,
again, on the FDA’s interpretation of chemical action.
It is worth noting that such classification is merely for
determining primary jurisdiction over the product. Even if the
FDA assigns a drug-device combination product to CDRH,
constituent parts of the product will still be regulated as needed
to assure safety and efficacy.114 That is, due to the broad
regulatory power vested in the FDA, it can later regulate such
products as it deems necessary and, in any event, the FDA will
maintain quality control requirements of the non-primary
components.115 Nonetheless, the PMOA determination and the
resulting combination product classification has significant
consequences due to the differing regulatory burdens between
drugs, devices, and biologics.116 Indeed, the differing PMOAbased determination of product classification has led to some
unintuitive and seemingly unfair outcomes.117 Recognizing that
this is an area of uncertainty for applicants, the Office of
Combination Products encourages applicants to submit an
informal inquiry or a Request for Determination (RfD) prior to
seeking premarket review of products for which classification is
uncertain.118 Applicants can further appeal such determinations
by way of a Request for Reconsideration.119

114. See U.S. Food & Drug Admin., GUIDANCE FOR INDUSTRY AND FDA
STAFF: CURRENT GOOD MANUFACTURING PRACTICE REQUIREMENTS FOR
COMBINATION PRODUCTS (2015), https://www.fda.gov/media/90425/download
(“The constituent parts of a combination product retain their regulatory status
(as a drug or device, for example) after they are combined.”).
115. Id.
116. See Genus Med. Tech. v. United States Food & Drug Admin., No. 19544 (JEB), 2019 U.S. Dist. LEXIS 210397 * 2019 WL 6683777 (indicating that
if a particular contrast agent were classified as a device it could obtain approval
for about $60,000, whereas obtaining drug approval would be “over half a
million dollars in addition to a continuing annual cost north of $186,000.”).
117. Response to Request for Designation from U.S. Food & Drug Admin., to
AWBAT Plus Wound Dressing (Dec. 3, 2009).
118. See Jurisdictional Information, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/combination-products/classification-and-jurisdictionalinformation (last updated Apr. 9, 2020).
119. Id.
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E. BARRIERS TO MARKET ENTRY
i.

Drugs

To market a new drug in the U.S., an innovator must submit
a new drug application (NDA) to the FDA demonstrating that
the drug is safe and effective for its intended use, and seek to
obtain the FDA’s express approval.120 For new drugs, applicants
can proceed through the premarket review process via either a
505(b)(1) NDA or a 505(b)(2) NDA (a type of “paper” NDA).121 In
either case, the NDA is intended to be a complete, candid, and
authoritative report of an applicant’s relevant knowledge arising
from scientific and clinical investigations of the drug.122
A 505(b)(1) NDA requires that applicants conduct and
report the results of their own well-controlled clinical studies
evaluating safety and efficacy.123 These clinical studies typically
take the form of Phase 0, Phase 1, Phase 2, and Phase 3 trials.124
The NDA must also include a complete description of the drug,
all components, its method of manufacture, its manufacturing
facility and controls, specimens of the drug, and proposed
labeling.125 Drugs are deemed to be a new molecular entity
(NME) if the structure of one of the active ingredients (i.e.,
“active moiety”) does not correspond to a previously approved
structure, or esters, salts, clathrate, and other noncovalent
derivatives thereof.126 Whether a drug is an NME is factor that
120. See 21 U.S.C. § 355(a) (2011).
121. See 21 U.S.C. § 355(b) (2011).
122. See 21 U.S.C. § 355(b)(1)(A) (2011). For example, the clinical studies
should have objective end points that are clinically relevant to the intended use,
should conform with good clinical practice, and should be conducted and
reported in a manner such that they are scientifically credible.
123. See 21 U.S.C. § 355(i)(2)(A) (2011).
124. Id.
125. See 21 U.S.C. § 355(b)(1)(B-F) (2011).
126. The FDA uses the NME designation for internal administration and
regulatory research purposes. Still, the classification is important because it
may guide internal policy and decision making. See U.S. FOOD & DRUG ADMIN.,
OFFICE OF PHARMACEUTICAL QUALITY, POLICY AND PROCEDURES: NDA
CLASSIFICATION CODES (2015), https://www.fda.gov/media/94381/download
(summarizing the various ways CDER classifies NDA products). See also 21
C.F.R. § 314.3 (2016) (“Active moiety is the molecule or ion, excluding those
appended portions of the molecule that cause the drug to be an ester, salt
(including a salt with hydrogen or coordination bonds), or other noncovalent
derivative (such as a complex, chelate, or clathrate) of the molecule, responsible
for the physiological or pharmacological action of the drug substance.”). The
FDA uses NCE, which relates to a five-year market exclusivity incentive for
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the FDA weighs when considering investigation new drug (IND)
applications,127 risk evaluation and mitigation strategies
(REMS) submissions, 128 and its evaluation of NDAs.129
In contrast with the 505(b)(1) process, a 505(b)(2) NDA can
reference a prior finding by the FDA of the same drug’s safety
and efficacy, published clinical data, or prior clinical
investigations conducted for someone other than applicant but
for which the applicant does not have right of reference.130 In a
505(b)(2) NDA, the applicant need only provide additional
clinical or scientific information in connection with the
difference between the new drug product and the prior approved
drug.131 A 505(b)(2) NDA is commonly used to pursue a new use,
indication, formulation, dosage, route of administration,
prodrug, or to label a previously approved drug.132 However, a
505(b)(2) NDA should not be used as a substitute entry point for
generic products that are below the bioequivalence requirements
of the 505(j) abbreviated new drug application (ANDA)
pathway.133
In considering whether to approve a new drug, the FDA
conducts a risk-benefit analysis that considers the applicant’s
bringing such products to market. See 21 C.F.R. § 314.108 (2012) (“New
chemical entity means a drug that contains no active moiety that has been
approved by FDA in any other NDA submitted under section 505(b) of the
Federal Food, Drug, and Cosmetic Act.”). See also U.S. FOOD & DRUG ADMIN.,
GUIDANCE FOR INDUSTRY: NEW CHEMICAL ENTITY EXCLUSIVITY
DETERMINATIONS FOR CERTAIN FIXED-COMBINATION DRUG PRODUCTS (2014),
https://www.fda.gov/media/87932/download (indicating that the NCE incentive
is determined based off of each drug substance, so mixtures of old and new APIs
can qualify for the NCE incentive).
127. See U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY AND REVIEW
STAFF: BEST PRACTICES FOR COMMUNICATION BETWEEN IND SPONSORS AND
FDA
DURING
DRUG
DEVELOPMENT
(2017),
https://www.fda.gov/media/94850/download (urging pre-IND meetings for
sponsors of NME INDs).
128. See 21 U.S.C. § 355-1 (2011).
129. See U.S. FOOD & DRUG ADMIN., HUMAN GENERIC DRUG PERFORMANCE
GOALS AND PROCEDURES FISCAL YEARS 2013 THROUGH 2017 (2012),
https://www.fda.gov/media/82022/download (setting forth a program for
improving transparency and communication surrounding NME NDAs).
130. U.S. FOOD & DRUG ADMIN., GUIDANCE OF INDUSTRY: APPLICATIONS
COVERED BY 505(b)(2) (1999), https://www.fda.gov/media/72419/download.
131. Id.
132. Id.
133. In other words, if the product to be approved is identical or generic to a
prior approved product, then it must be equal or better to be suitable for the
505(b)(2) pathway. Id.
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clinical data, currently-available alternative treatments, and
whether the risks can be addressed by risk management and
mitigation strategies (REMS).134 Refusal is typically on the basis
that the NDA fails to sufficiently establish that the drug is safe
and effective under the conditions set forth in the proposed
labeling.135 However, applications can also be refused on various
other grounds, including failure to list patents for submission to
the Orange Book, inadequate manufacturing controls, or the
FDA’s determination that a proposed label is false or
misleading.136 The NDA review and approval process is highly
technical and product-specific.137 To assist applicants and in the
interest of transparency, the FDA provides product-specific and
general guidances.138 The CDER further provides a directory
listing many of its internal policies and procedures with respect
to NDA approval.139
Generic drug makers can seek approval of follow-on
products by way of an ANDA, i.e., a 505(j), or by way of the
505(b)(2) approval process discussed above.140 The ANDA
process requires the applicant to show that the follow-on product
is bioequivalent, and has the same active ingredient, route of
administration, dosage form, and strength as a previouslyapproved reference product.141 21 C.F.R. § 314.3 defines
bioequivalence, active ingredient, dosage form, and strength.
134. See Drugs: Development and Approval Process, U.S. FOOD & DRUG
ADMIN., https://www.fda.gov/drugs/development-approval-process-drugs (last
updated Oct. 28, 2019) (explaining the FDA’s risk-benefit approach to drug
approval).
135. See 21 U.S.C. §§ 355(c)-(d) (2011) (setting forth approval, refusal, and
rationales for the same).
136. See 21 U.S.C. § 355(d) (2011).
137. See, e.g., U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY:
PRUSSIAN BLUE DRUG PRODUCTS—SUBMITTING A NEW DRUG APPLICATION
(2003), https://www.fda.gov/media/71071/download (providing guidance for a
particular class of products); see also U.S. FOOD & DRUG ADMIN., GUIDANCE FOR
INDUSTRY: BIOAVAILABILITY STUDIES SUBMITTED IN NDAS OR INDS—GENERAL
CONSIDERATIONS
(2019),
https://www.fda.gov/media/121311/download
(providing general guidance for how to best meet bioavailability requirement
for NDA applications set forth in 21 C.F.R. § 320).
138. Id.
139. CDER Manual of Policies & Procedures (MAPP), U.S. FOOD & DRUG
ADMIN., https://www.fda.gov/about-fda/center-drug-evaluation-and-researchcder/cder-manual-policies-procedures-mapp (last updated Apr. 17, 2020)
(providing a searchable directory of its published policies and procedures).
140. See 21 U.S.C. § 355(b)(1) (2011); see also 21 U.S.C. § 355(j) (2011).
141. See 21 U.S.C. § 355(j) (2011).
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The sameness of the active ingredient, i.e., drug substance, is
established by showing that the follow-on active has the same
chemical structure as the reference product.142 Bioequivalence is
typically shown by demonstrating an absence of significant
difference in bioavailability, which is the rate and extent to
which the active ingredient is absorbed into the bloodstream and
made available to the target treatment site.143 Alternative
approaches to showing bioequivalence exist but applicants often
do not have certainty regarding what approaches the FDA will
deem suitable,144 particularly for products that have not yet seen
generic entry.
As required by the Hatch-Waxman Act, the FDA publishes
a list of all approved NDA drugs in a compendium called the
Orange Book, together with a list of patents supplied by each
drug’s sponsor.145 Before any generic drug can be approved by
the FDA, whether under 505(j) or 505(b)(2), a generic drug
maker must first certify that marketing its generic drug would
not infringe any valid, listed patents.146 In this manner, the
regulatory approval process for generic drugs involves use of the
U.S. patent system, a separately regulatory regime, to act as a
secondary gatekeeper for generic approval.
ii. Devices
a. Class I, Class II, and Class III
The FD&C Act provides for a risk-based approach to device
regulation.147 Once a product is recognized as a device, CDRH
further classifies the device as Class I, Class II, or Class III,
142. See 21 U.S.C. § 320 (2012).
143. See 21 U.S.C. § 314.3 (2012); see also 21 U.S.C. § 320 (2012).
144. See U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY:
BIOEQUIVALENCE RECOMMENDATIONS FOR SPECIFIC PRODUCTS (2012),
https://www.fda.gov/media/71401/download (explaining FDA’s process for
conveying its bioequivalence expectations, which can be product specific and
deviate from general guidance).
145. See 21 U.S.C. § 355(b)(1) (2011); see also 21 C.F.R. § 314 (2012).
146. See 21 U.S.C. § 355(b)(2)(A) (2011); see also 21 U.S.C. § 355(j)(2)(vii)
(2011).
147. See 21 U.S.C. § 360c(a) (2011); see also U.S. FOOD & DRUG ADMIN.,
GUIDANCE FOR INDUSTRY AND FOOD AND DRUG ADMINISTRATION STAFF: FDA
AND INDUSTRY PROCEDURES FOR § 513(G) REQUESTS FOR INFORMATION UNDER
THE
FEDERAL
FOOD,
DRUG,
AND
COSMETIC
ACT
(2012),
https://www.fda.gov/media/78456/download (summarizing the FDA’s device
classification scheme).
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corresponding to what controls are warranted to assure safety
and efficacy.148 Class I devices are regulated by general controls
applicable to all devices.149 Class II devices are those that can be
sufficiently regulated by way of incorporating additional special
controls, but for which general controls are not themselves
sufficient to assure safety and efficacy.150 Class III devices are
typically devices that support or sustain human life and require
premarket approval due to greater risk of harm.151 The FDA
provides a searchable online database listing the device
classifications and the Federal Code is regularly updated with
classification details.152 A Section 513(g) request can be
submitted to the FDA to inquire what class a device falls within;
whether a PMA, 510(k), or neither, would be required before
bringing the product to market; and if any special requirements
or guidances apply to such product types.153 A device is
automatically assigned to Class III unless it is a type of device
already categorized by the FDA as Class I or Class II and the
148. See U.S. FOOD & DRUG ADMIN., supra note 147.
149. The FDA describes general controls as statutory requirements
authorized by FD&C Act. For example, general controls include the
adulteration and misbranding provisions, the premarket review processes, the
requirements to register drug and device producers, statutorily banned devices,
recall provisions, adverse event reporting, product tracking systems,
inspections, GMP requirements, public notices, and other notices. See
Regulatory Controls, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/medicaldevices/overview-device-regulation/regulatory-controls (last updated Mar. 27,
2018) (defining general controls and listing examples).
150. Special controls are described as regulatory requirements not
applicable to all devices and typically product specific, e.g., performance
standards, postmarket surveillance, patient registries, black box warnings and
other special labeling requirements, premarket data requirements, and
compliance with guidelines. See Regulatory Controls, U.S. FOOD & DRUG
ADMIN.,
https://www.fda.gov/medical-devices/overview-deviceregulation/regulatory-controls (last updated Mar. 27, 2018) (defining special
controls and listing examples).
151. Id.
152. See Product Code Classification Database, U.S. FOOD & DRUG ADMIN.
(2019),
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm; see
also 21 C.F.R. §§ 862–892 (2012) (listing virtually all medical device types along
with their classifications, product codes, and FDA premarket review
organizations).
153. See U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY AND FOOD
AND DRUG ADMINISTRATION STAFF: FDA AND INDUSTRY PROCEDURES FOR
SECTION 513(G) REQUESTS FOR INFORMATION UNDER THE FEDERAL FOOD,
DRUG, AND COSMETIC ACT (2012), https://www.fda.gov/media/78456/download
(summarizing the FDA’s current thinking on the 513(g) process).
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device is substantially equivalent to another device already on
the market as determined by a 510(k) submission.154 In response
to, or as an alternative to, the default classification of new
devices into Class III, a device manufacturer can submit a De
Novo Classification Request.155 In response, the FDA conducts a
risk-based evaluation of the device and assigns it to Class I or
Class II if general and special controls are sufficient to provide
reasonable assurance of safety and efficacy.156
b. Exempt Devices, 510(k), and Premarket Approval
Almost all Class I devices and some Class II devices are
exempted from the requirement to obtain premarket approval or
provide the FDA with premarket notification.157 Some Class I
devices are further exempted from satisfying GMP general
requirements, provided records and complaint files are kept, and
the device is not labeled as sterile when it is sold.158 The FDA
provides an online database of all exempt devices.159
The FDA requires premarket notification by way of a 510(k)
submission at least 90 days before a device is marketed in the
U.S. for the first time, or before a device already marketed is
modified in a manner which may significantly affect safety or
effectiveness.160 In some cases, changes to a product’s packaging
or label can require submission of a 510(k).161 This notification
requirement applies to every Class I, Class II, and Class III
medical device unless it is exempt or engaged in the separate

154. 21 U.S.C. § 513(f) (2019).
155. See U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY AND FOOD
AND DRUG ADMINISTRATION STAFF: DE NOVO CLASSIFICATION PROCESS
(EVALUATION
OF
AUTOMATIC
CLASS
III
DESIGNATION)
(2017),
https://www.fda.gov/media/72674/download (summarizing the De Novo
Classification pathway).
156. Id.
157. See Medical Device Exemptions 510(k) and GMP Requirements, U.S.
FOOD
&
DRUG
ADMIN.,
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/315.cfm (last accessed
Dec. 2, 2019) (listing medical devices exempt from premarket notification and
premarket approval requirements).
158. Id.
159. Id.
160. See Premarket Notification 510(k), U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/medical-devices/premarket-submissions/premarketnotification-510k (last updated Mar. 13, 2020).
161. Id.
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premarket approval (PMA) process.162 Devices subject to the
510(k) premarket requirement are not cleared for market until
the FDA provides a written order declaring that the device is
“substantially equivalent” to a predicate device and that it may
be marketed in the U.S.163
A device is deemed “substantially equivalent” to a predicate
device if the following criteria are satisfied: Firstly, it must have
the same intended use. Secondly, it must either have the same
technological characteristics, or, if it has different technology
characteristics that do not raise questions of safety and
effectiveness, the 510(k) submission must contain information
demonstrating that the new device is at least as safe and
effective as the predicate device.164 Technological characteristics
are deemed to be different if there is a significant change in the
materials, design, or energy source.165 In considering whether
there is substantial equivalence to a predicate device, the FDA
also looks at differences in manufacturing process, labeling, and
chemical composition.166 The use of nanotechnology in devices is
likely to make determinations of substantial equivalence and
technological sameness challenging.
The FDA has recently provided several alternative
pathways for manufacturers to show that their devices are
substantially equivalent.167 The Special 510(k) Program
provides a simplified pathway for manufacturers to update and

162. Id.
163. Id. 510(k) must also satisfy general controls and any prescribed special
controls. See Regulatory Controls, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/medical-devices/overview-device-regulation/regulatorycontrols (last updated Mar. 27, 2018).
164. See 21 U.S.C. § 360c(i) (2011); see also U.S. FOOD & DRUG ADMIN., supra
note 146; see also U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY AND
FOOD AND DRUG ADMINISTRATION STAFF: THE 510(K) PROGRAM: EVALUATING
SUBSTANTIAL EQUIVALENCE IN PREMARKET NOTIFICATIONS (2014),
https://www.fda.gov/media/82395/download (summarizing the 510(k) decision
making process, how the FDA interprets substantial equivalence, and how it
defines technological characteristics).
165. 21 U.S.C. § 360c(i)(1)(B) (2011).
166. U.S. FOOD & DRUG ADMIN., supra note 146.
167. See Tom Cowan, FDA Issues Guidance on “Abbreviated” and “Special”
510(k)
Pathways,
KNOBBE
MEDICAL,
http://knobbemedical.com/medicaldeviceblog/article/fda-issues-guidance-onabbreviated-and-special-510k-pathways/ (last visited Apr. 17, 2020).
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modify their own, previously cleared products.168 In a Special
510(k) submission, a manufacturer can establish substantial
equivalence by way of its own design controls and conformance
with quality system regulations.169 The Abbreviated 510(k)
Program facilitates approval of devices that have been the
subject of the FDA’s previously-issued product-specific
guidances, special control standards, or voluntary consensus
standards.170 In an abbreviated 501(k) application, a
manufacturer can establish substantial equivalence by following
such guidances or standards and assuring its conformance.171
Premarket Approval (PMA) is the most rigorous form of
premarket review that the FDA conducts for medical devices. 172
The PMA process is roughly analogous to an NDA or Biologics
License Application (BLA), except that the standard for approval
of a PMA is a “reasonable assurance” of safety and efficacy.173 A
PMA application involves submission of data from laboratory
and clinical studies, device and manufacturing details including
trade secret information, quality system controls, comparison to
commercially-available alternatives, and scientifically-based

168. U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY AND FOOD AND
DRUG ADMINISTRATION STAFF: THE SPECIAL 510(K) PROGRAM (2019),
https://www.fda.gov/media/116418/download (describing the new Special 510(k)
program and how to determine whether a product modification is suitable for
review under this program).
169. Id.
170. U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY AND FOOD AND
DRUG ADMINISTRATION STAFF: THE ABBREVIATED 510(K) PROGRAM (2019),
https://www.fda.gov/media/72646/download (summarizing the new Abbreviated
510(k) program and how to determine whether a product modification is
suitable for review it). See also U.S. FOOD & DRUG ADMIN., APPROPRIATE USE
OF VOLUNTARY CONSENSUS STANDARDS IN PREMARKET SUBMISSIONS FOR
MEDICAL
DEVICES
(2018),
https://www.fda.gov/media/71983/download
(explaining that voluntary consensus standards are effective regulatory tools
recognized in the FD&C Act per 21 U.S.C. § 360d(1)(A)).
171. U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY AND FOOD AND
DRUG ADMINISTRATION STAFF: THE ABBREVIATED 510(K) PROGRAM (2019),
https://www.fda.gov/media/72646/download (describing the new Abbreviated
510(k) program and how to determine whether a product modification is
suitable for review).
172. See Premarket Approval, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/medical-devices/premarket-submissions/premarketapproval-pma (last updated May 16, 2019); see also 21 C.F.R. § 814 (1996)
(outlining the PMA process).
173. Compare 21 U.S.C. § 393(b) (2011) with 21 U.S.C. § 355(j) (2011). See
also The Biologics Price Competition and Innovation Act of 2009, S. 1695, 100th
Cong. § 7002(e) (2007).
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conclusions linking the device’s medical claims to the results of
studies.174 The studies should be based on accepted scientific and
clinical practices and, when applicable, FDA guidances.175 In
evaluating safety and efficacy, the FDA considers the intended
patient population, the conditions for use of the device, the riskbenefit of the device, and the device’s reliability.176
Follow-on devices gain access to the market the same way
as new devices. For Class I and II, no premarket review is
required if the device is an exempted device; otherwise, the
manufacturer will likely proceed through a 510(k) process. If the
innovator device requires PMA, then follow-on devices will also
require a PMA unless the FDA down-classified the device class
in the interim.177 Moreover, the prior PMA approval would have
provided the innovator with six years of data exclusivity.178 PMA
devices do not have an abbreviated approval path that is
analogous to the generic ANDA pathway.179 The 510(k) path is
the closest approximation of a follow-on pathway in the device
framework, which although not used to reference clinical data,
is similarly used to obtain approval by pointing to an alreadyapproved product.
iii. Biologics
Biologics are regulated under the Public Health and Safety
Act (PHSA) which requires approval of a BLA prior to marketing
any biologic.180 Approval is based on the applicant establishing
that the product is safe, pure, and potent.181 The BLA process is
174. See PMA Application Contents, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/medical-devices/premarket-approval-pma/pmaapplication-contents (last updated May 16, 2019) (outlining required and
suggested elements of a PMA application).
175. See PMA Clinical Studies, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/medical-devices/premarket-approval-pma/pma-clinicalstudies (last updated Feb. 21, 2019) (summarizing best practices for clinical
investigations and factors that the FDA considers for safety and effectiveness).
176. See 21 U.S.C. § 860.7 (2012).
177. See Erika Leitzan, Data Exclusivity for Medical Devices, OBJECTIVE
INTENT (Oct. 10, 2017), https://objectiveintent.blog/2017/10/10/data-exclusivityfor-medical-devices/.
178. Id.
179. Id.
180. 42 U.S.C. § 262 (1993).
181. See Frequently Asked Questions About Therapeutic Biological Products,
U.S.
FOOD
&
DRUG
ADMIN.,
https://www.fda.gov/vaccines-bloodbiologics/development-approval-process-cber/biologics-license-applications-bla-
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largely analogous to an NDA and, in fact, the PHSA expressly
adopts for biologics all the general FD&C provisions except for
the replacement of the NDA process with a BLA.182 A BLA
differs from an NDA in that BLA holders can have more
stringent manufacturing validation requirements, must retain
certain product samples after expiration of each lot of product,
and have particular post-market responsibilities including
submission of reports regarding batch information and adverse
events.183
Due to the complexity of biologics as well as their economic
and therapeutic importance, Congress has provided unique
regulatory provisions for follow-on biologics products.184 The
Biologics Price Competition and Innovation Act (BPCIA)
provided for an abbreviated BLA pathway, analogous to an
ANDA, except that instead of requiring follow-on products to
have identical structure and activity. The BPCIA permits
approval of “biosimilar” products that are merely expected to
produce the same clinical result.185 The FDA defines a product
as a biosimilar when there are “no clinically meaningful

process-cber (last updated Feb. 2, 2018) (defining biological products and
summarizing certain ways that approval of biological products differs from the
drug approval process).
182. 42 U.S.C. §262(j) (1993).
183. See Keith Webber, FDA’s Interpretation of the “Deemed to Be a License”
Provision of the Biologics Price Competition and Innovations Act, FDA WATCH,
https://www.lachmanconsultants.com/wp-content/uploads/2019/03/deemed-tobe-a-license-20-22-FDA-0319.pdf (summarizing the differences between an
NDA and BLA).
184. See The Biologics Price Competition and Innovation Act of 2009, S.
1695, 100th Cong. § 7002(e) (2007) (creating an accelerated approval system for
biological products that are biosimilar to, or interchangeable with, an FDA
licensed reference biological product).
185. U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY:
CONSIDERATIONS IN DEMONSTRATING INTERCHANGEABILITY WITH A
REFERENCE PRODUCT (2019), https://www.fda.gov/media/124907/download
(reporting on recent developments in the biosimilar approval process); see also
U.S. FOOD & DRUG ADMIN., GUIDANCE CLINICAL PHARMACOLOGY DATA TO
SUPPORT A DEMONSTRATION OF BIOSIMILARITY TO A REFERENCE PRODUCT
(2016), https://www.fda.gov/media/88622/download; U.S. FOOD & DRUG ADMIN.,
GUIDANCE QUESTIONS AND ANSWERS ON BIOSIMILAR DEVELOPMENT AND THE
BPCI ACT GUIDANCE FOR INDUSTRY (2018), https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents/questions-and-answersbiosimilar-development-and-bpci-act-guidance-industry; U.S. FOOD & DRUG
ADMIN., INTERPRETING SAMENESS OF MONOCLONAL ANTIBODY PRODUCTS
UNDER
THE
ORPHAN
DRUG
REGULATIONS
(2014),
https://www.fda.gov/media/77256/download.
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differences” between the reference product in terms of safety,
purity, and potency.186 However, a biosimilar is not so similar
that, for any given patient, one can assume the same clinical
result when switching from the reference product.187 The
omission of any requirement for structural sameness or
bioequivalence is a key distinction between generic drugs and
biosimilars.188 In some cases, biosimilars can be shown to be
interchangeable, on the basis of additional clinical testing and
analysis of switching risks.189 An “interchangeable” biosimilar
may be substituted for the reference product at the pharmacylevel without requiring physician intervention.190 Biosimilars
are a particularly active area of regulatory development as the
FDA and Congress are still exploring how ‘similar’ biosimilars
should be.191
Additionally, unlike the generic approval process for drugs,
the approval process for biologics does not tether the FDA to the
patent system. Instead, BLA approval of follow-on products
follows a process that is separate from an innovator’s patent
enforcement efforts.192
F. CONSEQUENCES OF PRODUCT CLASSIFICATION
Product classification is a critical determining factor of the
time and cost of obtaining regulatory approval. Development
and approval of drugs and biologics involves enormous costs,
estimated to be as high as $100 million to $2 billion.193 Yet, a
device can be developed and approved with as little as $1 million
186. Biosimilar and Interchangeable Products, U.S. FOOD & DRUG ADMIN.
(Oct.
2017),
https://www.fda.gov/drugs/biosimilars/biosimilar-andinterchangeable-products#biosimilar.
187. This limits the ability of a pharmacy to substitute certain biosimilars
for pioneer biologic without the agreement of the prescriber. Id.
188. Id.
189. Id.
190. Id.
191. Id.
192. Cf. 42 USC § 262(l) (1993) (allowing the so-called “patent dance” process
in which biosimilar entrants can negotiate an initial, early wave of patent
litigation during the BLA process, although the FDA’s approval does not hinge
on any particular litigation outcome).
193. Thomas Sullivan, A Tough Road: Cost to Develop One New Drug Is $2.6
Billion; Approval Rate for Drugs Entering Clinical Development Is Less Than
12%, POL’Y & MED., https://www.policymed.com/2014/12/a-tough-road-cost-todevelop-one-new-drug-is-26-billion-approval-rate-for-drugs-entering-clinicalde.html (last updated Mar. 21, 2019).

2020]

COMPLEX PRODUCTS

513

to $10 million if its developer can follow a 510(k) path.194 Even
in the case of a device PMA, estimated to have an average cost
between $10 million and $100 million, costs are still typically far
below the average cost of development and approval of NDA and
BLA products.195 Moreover, bringing a new drug or biologic to
market takes far longer, about twelve years on average, which
would typically include about two years of pre-clinical testing,
about eight years of clinical trials, and about two years of
NDA/BLA approval.196 In contrast, bringing a new device to
market averages between three and seven years.197 The new
device timeline would typically include two to three years of preclinical bench and animal testing (which can sometimes be
sufficient to show that a 510k device is substantially equivalent)
and can also involve one to two years of clinical trials, which may
involve a thousand or more patients.198
This eight-year difference in timeline is enormously
meaningful. Each additional year of clinical investigation and
regulatory review not only delays a future income stream, but
also eats away at the remaining term of the product’s patents.199

194. See Medical Device User Fees, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/medical-devices/premarket-submissions/medical-deviceuser-fees (last updated Jan. 14, 2020) (discussing the different fee and payment
structures of submitting a drug to the FDA); See also U.S. FOOD & DRUG
ADMIN., GUIDANCE FOR INDUSTRY AND FOOD AND DRUG ADMINISTRATION
STAFF: BUNDLING MULTIPLE DEVICES OR MULTIPLE INDICATIONS IN A SINGLE
SUBMISSION (2007), https://www.fda.gov/media/73500/download (discussing a
method of cutting down costs by bundling multiple products into one
application).
195. See U.S. FOOD & DRUG ADMIN. supra note 194 (discussing the different
fee and payment structures of submitting different types of drugs to the FDA
for approval).
196. Gail A. Van Norman, Drugs, Devices, and the FDA: Part 1: An Overview
of Approval Processes for Drugs, 1 JACC: BASIC TO TRANSLATIONAL SCI. 70, 70–
79 (2016); see also Matthew Herper, The Cost of Creating a New Drug Now $5
Billion, Pushing Big Pharma to Change, FORBES (Aug. 11, 2013),
https://www.forbes.com/sites/matthewherper/2013/08/11/how-the-staggeringcost-of-inventing-new-drugs-is-shaping-the-future-of-medicine/#7753cc096bfc.
197. Gail A. Van Norman, Drugs, Devices, and the FDA: Part 2: An Overview
of Approval Processes: FDA Approval of Medical Devices, 1 JACC: BASIC TO
TRANSLATIONAL SCIENCE 277, 277–87 (2016).
198. U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY AND FOOD AND
DRUG ADMINISTRATION STAFF: FORMAT FOR TRADITIONAL AND ABBREVIATED
510(K)S (2019), https://www.fda.gov/media/130647/download (discussing the
timeline for submission and approval of 510(k) devices).
199. Lifetime Trends in Biopharmaceutical Innovation, QUINTILESIMS (Jan.
2017),
https://www.statnews.com/wp-
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The shorter the remaining patent term, the higher the company
will need to set its prices in order to counterbalance its
development and opportunity costs. If the remaining patent
timeline is too short, then development and commercialization
of the product may not be justified.
Each of the different regulatory pathways reward
applicants with differing periods of data and market
exclusivity.200 For example, drug products representing a new
chemical entity (NCE) having a new active moiety201 and
approved under an NDA pathway will typically be provided with
five years of data exclusivity per the Hatch-Waxman Act, 202
which also effectively provides more than seven years of market
exclusivity by way of a thirty-month stay pending generic
entry.203 Other clinical investigations, for example, studying a
substantial change to a previously approved drug, can provide
three years of market exclusivity.204 Devices can be provided
with six years of data exclusivity after approval of a PMA.205
Approval of biologic under the BLA pathway provides four years
of data exclusivity and twelve years of market exclusivity. 206
Various additional incentives further apply to each, such as the
six-month extension of exclusivity provided for pediatric testing
and the seven-year market exclusivity provided by the Orphan

content/uploads/2017/01/Lifetime_Trends_in_Biopharmaceutical_Innovation.p
df.
200. See Bo Peng & Marta C. Tomas, A Cheat Sheet to Navigate the Complex
Maze of Exclusivities in the United States, 3 PHARMACEUTICAL PAT. ANALYST
339 (Oct. 7, 2014), https://www.future-science.com/doi/10.4155/ppa.14.30.
201. Here, the term “active moiety” simply refers to a new drug substance,
not just a new pharmacophore portion of drug. The term “new active moiety”
serves to distinguish from previously FDA-approved drug substances, and
esters, salts, and clathrates thereof. See Scott Whittaker & Anthony Walker,
Pharmaceutical Patent Term Extension: An Overview, ALACRITA,
https://www.alacrita.com/whitepapers/pharmaceutical-patent-term-extensionan-overview (last accessed Apr. 16, 2020).
202. 34 U.S.C. § 156(g)(6)(C) (2018).
203. Id.
204. Small Business Assistance: Frequently Asked Questions for New Drug
Product
Exclusivity,
U.S.
FOOD
&
DRUG
ADMIN.
(2016),
https://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/smallbusiness-assistance-frequently-asked-questions-new-drug-product-exclusivity.
205. See Erika Lietzan, Data Exclusivity for Medical Devices, OBJECTIVE
INTENT (Oct. 10, 2017) https://objectiveintent.blog/2017/10/10/data-exclusivityfor-medical-devices/ (summarizing the different data exclusivity provisions
regarding different medical devices).
206. Id.
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Drug Exclusivity incentive for treatment of a rare disease
affecting fewer than 200,000 people in the United States.207
Drug and biologic products can also take advantage of the
Qualified Infectious Disease Product exclusivity which provides
five years of supplemental market exclusivity.208 Patent term
extensions of up to five years are granted to one of a sponsor’s
U.S. patents covering the product for which premarket testing
approval was required.209
As discussed in Section E, classification also controls how
follow-on competition is regulated. A table is provided below that
summarizes the differences between the drug, device, and
biological regulatory schemes.
Table 4. Summary of Differences Between Regulatory
Pathways
Drug
Device
Biologic
Premarket
NDA
PMA, 510(k), or
BLA
Review
none depending on
risk
Average Time
12 years
3–7 years
12 years
for
Preclinical,
Clinical, and
Approval
Average Cost
$100M–$2B
$1M–$100M
$100M-$2B
for Approval
Data
Exclusivity

5 years
(Paragraph IV
can be
submitted at 4
years)

6 years

4 years

207. FDA Exclusivity and Generic Drugs: What Does It Mean?, U.S. FOOD &
DRUG
ADMIN.,
https://www.fda.gov/drugs/development-approval-processdrugs/frequently-asked-questions-patents-and-exclusivity (last updated Feb. 5,
2020).
208. US. FOOD & DRUG ADMIN., DRAFT GUIDANCE, QUALIFIED INFECTIOUS
DISEASE PRODUCT DESIGNATION QUESTIONS AND ANSWERS GUIDANCE FOR
INDUSTRY (2018), https://www.fda.gov/media/111091/download.
209. U.S. FOOD & DRUG ADMIN., PATENTS AND EXCLUSIVITY (2015),
https://www.fda.gov/media/92548/download.
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7.5 years (5
years plus 30month stay)
≤ 5 years

12 years
≤ 5 years

≤ 5 years

505(j)

510(k) Pathway

Same route of
administratio
n, dosage
form, and
strength, and
bioequivalence

Substantial
equivalence

Biosimilar
Pathway
Can be
expected to
produce the
same clinical
result in any
given
patient211

210

II. ANALYSIS
A. COMPLEX PRODUCTS HAVE COMPLEX PROBLEMS
i.

The Problem of Rising Healthcare Costs

Congress is increasingly concerned with the rising costs of
healthcare and is searching to find new ways to lower
prescription drug costs.212 Medical innovation is an expensive
and uncertain process. The cost of this uncertainty is reflected
in the enormous amount of resources required to develop new
medical products. After accounting for the cost of clinical
failures, the total cost of developing a new drug is now estimated

210. See 21 U.S.C. §355(j)(8)(B) (2010) (defining bioequivalence when the
rate and extent of absorption of the reference drug do not show a significant
difference).
211. U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY:
CONSIDERATIONS IN DEMONSTRATING INTERCHANGEABILITY WITH A
REFERENCE PRODUCT (2019), https://www.fda.gov/media/124907/download
(summarizing recent developments in the biosimilar approval process).
212. See Shelley Starkey, Congress Seeks to Address Rising Health Care
Costs, NAT’L COUNCIL FOR BEHAV. HEALTH (May 30, 2019),
https://www.thenationalcouncil.org/capitol-connector/2019/05/congress-seeksto-address-rising-health-care-costs/; see also FDA Drug Competition Action
Plan, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/drugs/guidancecompliance-regulatory-information/fda-drug-competition-action-plan
(last
updated Apr. 8, 2020).
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to be as high as $2.6 billion, but of which sixty percent is
incurred during clinical validation and FDA approval.213 Drug
candidates can expect a failure rate of more than ninety percent
and costs of approximately $1.5 billion during clinical testing
and regulatory approval—that is, most costs are incurred under
the purview of seeking regulatory approval and within
frameworks set forth by the FDA.214 The cost and risk of
development necessarily leads to high drug costs, as innovators
seek to justify their development expenses while earning a
return on capital commensurate with their risks of failure. The
factors that determine pricing of medical products are
enormously complex, including the cost of existing standard of
care, perceived value, payor dynamics, patient population,
length of treatment, geography, and even soft factors like payor
outcry or political concerns.215 What is clear, at least, is that
competition can significantly reduce average prices.216 Entry of
a single competitive generic product can lower prices by thirty to
forty percent, while the presence of six or more competitive
products can lower prices by up to ninety-five percent.217
Complex Products, however, can involve both high development
costs and unique barriers to competitor entry—this is a recipe
for runaway drug costs.
Recent reports from the U.S. GAO identify Complex
Products as an important area for further regulatory
development.218 The GDUFA, reauthorized in 2017 (GDUFA II)
213. Prescription Medicines: Costs in Context, PHARM. RES. & MFRS. AM.,
http://phrma-docs.phrma.org/sites/default/files/pdf/prescription-medicinescosts-in-context-extended.pdf (last updated Aug. 2016).
214. C. Heem et al., Estimation of Clinical Trial Success Rates and Related
Parameters,
20
BIOSTATISTICS
273,
273–86
(Apr.
2019),
https://academic.oup.com/biostatistics/article/20/2/273/4817524.
215. See, e.g., STAFF OF COMMITTEE OF FINANCE, 114TH CONG., THE PRICE
OF SOVALDI AND ITS IMPACT ON THE U.S. HEALTHCARE SYSTEM 1, 1–28 (Comm.
Print
2014),
https://www.govinfo.gov/content/pkg/CPRT114SPRT97329/html/CPRT-114SPRT97329-Part1.htm (discussing the pricing
method used to price the drug Sovaldi incorporating these factors).
216. WAYNE WINEGARDEN, PACIFIC RESEARCH INSTITUTE, THE ECONOMICS
OF
PHARMACEUTICAL
PRICING
5,
5–27
(2014),
https://www.pacificresearch.org/wpcontent/uploads/2017/06/PhamaPricingF.pdf.
217. Generic Competition and Drug Prices, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/about-fda/center-drug-evaluation-and-researchcder/generic-competition-and-drug-prices (last updated Dec. 13, 2019).
218. See generally U.S. GOV’T ACCOUNTABILITY OFF., GAO-18-80, GENERIC
DRUGS: FDA SHOULD MAKE PUBLIC ITS PLANS TO ISSUE AND REVISE GUIDANCE
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under the FDA Reauthorization Act of 2017 (FDARA), requires
the FDA to develop a program to facilitate approval of Complex
Product, especially generics.219 The FDA issued formal letters
committing to these goals and summarizing specific steps it
would take.220 These letters, representing a decade of associated
regulatory objectives, expressly identify Complex Products as an
area requiring further science-based regulatory development.221
Prior to departing from the FDA in 2019, former FDA
Commissioner Scott Gottlieb suggested that legislators further
consider changing Hatch-Waxman to accommodate complex
drugs.222 On January 17, 2020, the House Committee on Energy
NONBIOLOGICAL
COMPLEX
DRUGS
12
(2017),
https://www.gao.gov/assets/690/689047.pdf;
see
also
U.S.
GOV’T
ACCOUNTABILITY OFFICE, GAO-17-452, GENERIC DRUG USER FEES:
APPLICATION REVIEW TIMES DECLINED, BUT FDA SHOULD DEVELOP A PLAN
FOR
ADMINISTERING ITS UNOBLIGED USER FEES 6–14 (2017),
https://www.gao.gov/assets/690/684950.pdf (identifying generic competition
around complex drugs to have unique scientific and regulatory challenges and
should be a primary focus area for regulatory development).
219. See e.g., FDA Reauthorization Act of 2017, Pub L. No. 115-52, 131 Stat.
1005 (2017) (providing provisions to facilitate generic drug approval, including
of complex products); see generally GENERIC COMPLEX DRUGS SAFETY AND
EFFECTIVENESS FOR PATIENTS ACT OF 2015, H.R. 1576, 114TH CONG. (2015) (a
failed bill proposing to require a study by the Government Accountability Office
(GAO) to assess the Food and Drug Administration’s current regulatory
pathway for reviewing generic versions of nonbiologic complex drug products).
220. Here, the FDA’s performance goals relate primarily to providing
product specific guidances. GDUFA II sets an ambitious timeline for the FDA
to issue product-specific guidance for new generics for ninety percent of drugs
having NDAs approved after October 1st, 2017, though this timeline does not
apply to Complex Products, which have scientific and regulatory research
challenges. See U.S. FOOD & DRUG ADMIN., GENERIC DRUG PERFORMANCE
GOALS
AND
PROCEDURES
FISCAL
YEARS
2018-2022
(2016),
https://www.fda.gov/media/101052/download (exempting Complex Products
from its product-specific timeline).
221. See U.S. FOOD & DRUG ADMIN., HUMAN GENERIC DRUG PERFORMANCE
GOALS AND PROCEDURES FISCAL YEARS 2013 THROUGH 2017 (2012),
https://www.fda.gov/media/82022/download (summarizing various FDA goals
related to Complex Products, including continued development of science-based
recommendations for Complex Products, and the FDA’s intention to issue
guidances to clarify its recommendations); See also U.S. FOOD & DRUG ADMIN.,
GENERIC DRUG PERFORMANCE GOALS AND PROCEDURES FISCAL YEARS 20182022 (2016), https://www.fda.gov/media/101052/download (providing a preANDA pathway to facilitate development and approval of generic Complex
Products).
222. Beth Wang, Gottlieb: Changes to Hatch-Waxman May Boost Complex
Generic Market, INSIDEHEALTHPOLICY (Apr. 4, 2019, 12:09PM),
https://insidehealthpolicy.com/daily-news/gottlieb-changes-hatch-waxmanmay-boost-complex-generic-market (stating that the FDA chief “told lawmakers
ON
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and Commerce sent a letter to the FDA voicing its concerns
regarding lagging approvals of Complex Products and
demanding documents reflecting the FDA’s efforts to date.223
Currently, Complex Products are regulated according to the
FDA’s conventional regulatory scheme based on whether the
product is classified as a drug, device, biologic, or combination
product. To the extent Complex Products raise new challenges,
the FDA has preferred to approach each product on a case-bycase basis as scientifically-grounded guidance cannot be easily
generalized across Complex Products.224 The FDA’s current
efforts to facilitate approval of Complex Products are centered
around increasing transparency, for example, by way of
guidance225 on frequent trouble areas, reasoning that doing so
will lead to better prepared applicants and fewer unexpected
regulatory outcomes.226 The FDA is expected to issue new
guidance on Complex Products soon.227 To encourage
competition, the FDA has started publishing a list of all off-

they could contemplate changes to Hatch-Waxman that would allow the agency
to look at small complements of clinical data when approving generics of
complex drugs”).
223. Letter from Frank Pallone, Chairman Comm. Energy and Commerce,
et al., to Stephen Hahn, Comm’r of U.S. Food & Drug Admin. (Jan. 17, 2020)
(on file with House Energy Committee).
224. Jon S. B. de Vlieger et al., Report of the AAPS Guidance Forum on the
FDA Draft Guidance for Industry: “Drug Products, Including Biological
Products, that Contain Nanomaterials”, 21 AM. ASS’N OF PHARM. SCIENTISTS
55, 55 (Apr. 17, 2019), https://doi.org/10.1208/s12248-019-0329-7 (summarizing
a meeting discussing appropriate regulatory pathways for drug products
containing nanomaterials).
225. See
Guidances,
U.S.
FOOD
&
DRUG
ADMIN.,
https://www.fda.gov/industry/fda-basics-industry/guidances (last updated May
24, 2018) (describing the FDA’s use of guidance documents).
226. See U.S. FOOD & DRUG ADMIN., supra note 88 (defining chemical action
and explaining the FDA’s current thinking on the same).
227. See Upcoming Product-Specific Guidances for Complex Generic Drug
Product
Development,
U.S.
FOOD
&
DRUG
ADMIN.,
https://www.fda.gov/drugs/guidances-drugs/upcoming-product-specificguidances-complex-generic-drug-product-development (last updated Mar. 2,
2020) (listing complex products for which FDA plans to provide additional
product specific guidances). Such guidances are in line with FDA’s GDUFA II
commitment letter and Congress’s mandate under FDAMA. See, e.g., U.S. FOOD
& DRUG ADMIN., GENERIC DRUG PERFORMANCE GOALS AND PROCEDURES
FISCAL YEARS 2018-2022 (2016), https://www.fda.gov/media/101052/download;
see also FDA REAUTHORIZATION ACT OF 2017, PUB. L. NO. 115-52, §§501-905,
131 STAT. 1005, 1036– 90 (2017) (providing provisions to facilitate generic drug
approval, including generic complex products).

520

MINN. J. L. SCI. & TECH.

[Vol. 21:2

patent approved drugs that have no generic competition.228 The
FDA has also committed to issuing more product-specific
guidance, targeting ninety percent of all new chemical entity
drugs, but does not expect to meet that mark for Complex
Products.229 Product specific guidance for Complex Products
requires the development of scientific recommendations.230 The
FDA has also set up a Pre-ANDA Program and a mid-review
meeting program to assist applicants developing Complex
Products.231 The goal of the program is to speed up the approval
process for generic Complex Products, but also to inform
innovators regarding the FDA’s intended approach for
bioequivalence alternatives and other product-specific
challenges.
Each of these programs aim to decrease regulatory
uncertainty and facilitate competition primarily by increasing
FDA communication. However, the challenges surrounding
Complex Products are statutory and technical in nature, not a
result of lacking FDA transparency. The statutory problem is
that the FD&C Act relies on inherently flawed chemistry-based
distinctions to delineate its regulatory framework. The

228. List of Off-Patent, Off-Exclusivity Drugs Without an Approved Generic,
U.S. FOOD & DRUG ADMIN., https://www.fda.gov/drugs/abbreviated-new-drugapplication-anda/list-patent-exclusivity-drugs-without-approved-generic (last
updated Dec. 13, 2019). See also Approved Drug Products with Therapeutic
Equivalence Evaluations (Orange Book), U.S. FOOD & DRUG ADMIN.,
https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm. (last updated Apr.
2020) (listing all approved drug products, including corresponding patents that
must be overcome prior to marketing a generic).
229. See U.S. FOOD & DRUG ADMIN., HUMAN GENERIC DRUG PERFORMANCE
GOALS
AND
PROCEDURES
FISCAL
YEARS
2013-2017
(2012),
https://www.fda.gov/media/82022/download (summarizing various FDA goals
related to Complex Products, including continued development of science-based
recommendations for Complex Products, and FDA’s intention to issue guidances
to clarify its recommendations); see also U.S. FOOD & DRUG ADMIN., GENERIC
DRUG PERFORMANCE GOALS AND PROCEDURES FISCAL YEARS 2018-2022 (2016),
https://www.fda.gov/media/101052/download (providing a pre-ANDA pathway
to facilitate development and approval of generic Complex Products).
230. Id.
231. See U.S. FOOD & DRUG ADMIN., FORMAL MEETINGS BETWEEN FDA AND
ANDA APPLICANTS OF COMPLEX PRODUCTS UNDER GDUFA: GUIDANCE FOR
INDUSTRY (2017), https://www.fda.gov/media/107626/download (explaining that
mid-review-cycle meetings are used “to discuss issues identified during review
with the applicant”); see also U.S. FOOD & DRUG ADMIN., GDUFA II
COMMITMENT LETTER (2016), https://www.fda.gov/media/101052/download
(providing a pre-ANDA pathway to facilitate development and approval of
generic Complex Products).
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technological problem is that development of follow-on
competition for Complex Products requires substantial, but
redundant, technological efforts on the part of each applicant.
ii. The Problem with Chemical Action
Congress requires the FDA to distinguish devices from
drugs and biologics based on whether the intended therapeutic
function involves chemical action on the human or animal body,
or if the function is dependent on metabolism. However, the
precise meaning of chemical action is a frequent area of
confusion that leads to significant uncertainty, particularly in
the case of drug-device combinations and products having both
device-like and drug-like characteristics.232 The FDA’s reliance
on this distinction has led to unintuitive product
classifications.233 For drug-device combination products,
nanodevices, or other devices involving nanotechnology, the
uncertainty of classification poses a significant regulatory risk.
Experts have wrestled with how to rationalize the chemical
action requirement in a manner that provides a predictable
result. One analysis suggests interpreting chemical action
occurs when there is (1) a chemical transformation occurring at
the site of treatment and involving the article, (2) the
transformation is causally linked to the therapeutic effect, and
(3) the transformation is consistent with concepts currently
considered as chemistry.234 While this is a useful framework,

232. See FDA Finalizes Product Classification Guidance, FDA L. BLOG (Oct.
3,
2017),
http://www.fdalawblog.net/2017/10/fda-finalizes-productclassification-guidance/ (explaining how earlier draft guidance topics on the
subject of chemical action were criticized by numerous objections); see also Drug
or Device?—FDA Provides More Clarity—Or Does It?, CAMARGO BLOG (Oct. 11,
2017),
https://camargopharma.com/resources/blog/drug-device-fda-clarity
(explaining that the FDA issued a guidance document in response to the
difficulty in understanding whether “a combination product would be reviewed
as a device or a drug”); see generally Koolage & Hall, supra note 97 (discussing
what is meant by “chemical action” and its significance).
233. See Letter from Dep’t of Health and Human Services to Dr. Ronald A.
Sherman (Oct. 7, 2002) (online at https://www.fda.gov/media/74541/download)
(explaining that “medical maggots do not meet the definition of a medical device
in that that they appear to achieve their primary intended purpose through
chemical action” and are instead “a biological product, as defined by the Public
Health Service Act”).
234. See Koolage & Hall, supra note 97, at 1414.
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there remains a question about what types of transformations
should be deemed to be consistent with chemistry.235
Recent FDA guidance regarding chemical action attempts to
further define chemical action by introducing the concept of
interaction “at the molecular level” and mediating “a bodily
response” or altering a foreign entity’s interaction with the
body.236 The guidance also clarifies that chemical action excludes
interactions mediated solely by thermal and electromagnetic
radiation.237 This updated definition provides surprisingly little
clarity when considering Complex Products and other devicelike products having functional nanotechnology-based
features.238 Indeed, the definition permits such a broad
definition of chemical action that it encompasses virtually any
interaction beyond purely electromagnetic and kinetic energy
transfers.
As the “central” science, chemistry describes the
mechanisms by which virtually all substances interact. When
examined on the molecular or “nano” scale, virtually all medical
products interact with their surroundings by way of chemical
interactions. For example, even a scalpel can be described as
involving chemical action: the tool disrupts Van der Waals239
235. It may be easier to carve things away from chemistry if looking
“downward” toward the field of physics rather than “upward” toward molecular
ensembles and macroscopic phenomena. For example, one could carve out
physical phenomena such as universal force interactions, subatomic changes,
quantum-based changes, and changes in internal molecular states like
vibrational, translational, and thermal energy states. This appears to be what
the FDA has determined in its recent guidance and is similar to the
“chemicality” principal suggested by Koolage and Hall. See id. at 1410–11.
However, both of these approaches do not address how to delineate between
nonspecific chemical interactions, chemically-specific resulting from
macroscopic devices, device-like interactions on the nanoscale, and other
nanotechnology-type interactions that rely on aspects like structural design,
particle size, pore size, and machine-like mechanics.
236. See U.S. FOOD & DRUG ADMIN., supra note 88 at 7 (“[A] product exhibits
‘chemical action’ if it interacts at the molecular level with bodily components
(e.g., cells or tissues) to mediate (including promoting or inhibiting) a bodily
response, or with foreign entities (e.g., organisms or chemicals) so as to alter
that entity’s interaction with the body.”).
237. Id. at n.12.
238. See generally Raj Bawa et al., Nanopharmaceuticals: Patenting Issues
and FDA Regulatory Challenges, 5 A.B.A. SCITECH LAW, no. 2, 2008, at 2–3
(describing the FDA’s regulatory framework for nanopharmaceuticals)..
239. Van der Waals forces are electrical interactions that provide the
adhesive force that holds complex mixtures (like the human body) together. All
molecules have a given distribution of positive and negative charge across the
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interactions and non-covalent bonding240 while stretching and
separating tangled biopolymers to divide tissue.241 Consider a
very tiny scalpel: Is there a point at which the scalpel is so small
that it becomes a drug? Should it matter whether someone is
controlling the scalpel or whether the scalpel is adapted for a
specific type of tissue or biopolymer? Existing explanations of
chemical action have trouble distinguishing between drugs and
devices when both products can be said to interact with the body
via the same type of chemical interactions.242
These are the types of interactions one would expect in
Complex Products like low-weight heparins and carbohydrate
complexes. For example, pentosan polysulfate sodium is a lowweight “heparin-like macromolecular carbohydrate derivative”
indicated for relief of interstitial cystitis.243 It is classified by the
FDA as a drug.244 While its structure and mechanism are not
fully known, the drug is thought to collect on the bladder wall
and adhere to mucosa, thus serving as a protective coating.245
Here, the therapeutic effect of the drug is unlikely to involve any
chemical changes of the article itself. Instead, the drug likely
interacts with the body by way of non-specific electrostatic and
non-covalent intermolecular interactions. These are the same
chemical interactions that govern most macroscopic
interactions, such as the adhesiveness of a bandage, the
lubricating and cushioning effect of an ointment, the ability of
soap to dislodge filth, and the cohesive integrity of artificial
electron cloud that constitutes the molecule’s structure, but the presence of
other molecules nearby shifts this charge distribution. Naturally, some parts of
one molecule will tend toward positive, while parts of another will tend toward
negative. Van der Waals forces can be thought of as the result of these attractive
interactions.
240. Non-covalent bonding includes hydrogen bonding, which mediates
many solvent-based effects and protein folding.
241. See generally J.G. Williams et al., Fundamentals of Cutting, 6
INTERFACE FOCUS 1 (2016) (discussing the mechanics of cutting),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843621/pdf/rsfs20150108.pdf.
242. For example, interacting with the body via non-bonding Van der Waals
interactions and generalized non-covalent intermolecular binding.
243. Elmiron,
U.S.
FOOD
AND
DRUG
AMIN.,
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020193s009lbl.pdf
(last accessed Apr. 17, 2020).
244. See U.S. FOOD & DRUG ADMIN., LIST OF OFF-PATENT, OFF-EXCLUSIVITY
DRUGS
WITHOUT
AN
APPROVED
GENERIC
(2019),
https://www.fda.gov/media/133524/download (listing pentosan polysulfate
sodium as a drug).
245. See Elmiron, supra note 238.
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skin.246 The fields of statistical mechanics and material science
provide models relating how macroscopic activity relates to
chemical activity.247 A detailed enough inquiry of any given
therapeutic effect should virtually always uncover some type of
chemical action.248
Lastly, even if a consistent rationale can be provided to
delineate between drugs and devices based on chemical action,
there is a problem that such a rationale may not ultimately line
up with Congress’s primary purpose for such a distinction. Any
valid interpretation of Congress’s purpose should reflect a nonarbitrary policy goal.
iii. The Problem with the Sameness Requirement for Drugs.
Classification as a drug, rather than as a device or biologic,
results in enormous consequences for later follow-on
development of competitor products. For drugs, the path for
follow-on approval, an ANDA, is achieved by developing a
generic having the same active ingredient, route of
administration, dosage form, and strength as a previously
approved reference product, and showing bioequivalence of the
same. That is, the pathway for follow-on drugs requires
sameness, and thus is far narrower than the pathway for
biosimilars and 510(k) devices.249 This sameness requirement
arose during an era when most drugs were based on small
molecules that could be evaluated based on bioavailability and
246. See Benjamin E. Russ, What Exactly Is the Physical or Chemical Process
that Makes Adhesive Tape Sticky?, SCI. AM. (July 14, 1997),
https://www.scientificamerican.com/article/what-exactly-is-the-physi/
(explaining “[w]hen two materials are brought into contact with each other, the
surface molecules interact, giving rise to attractive forces that may be physical,
chemical, or electrostatic”).
247. See HARVEY GOULD & JAN TOBOCHNIK, STATISTICAL AND THERMAL
PHYSICS WITH COMPUTER APPLICATIONS 2 (2010) (characterizing statistical
mechanics as “a bridge between the microscopic and macroscopic worlds”).
248. On the other hand, one rigorous philosophical inquiry has suggested
that the presence of chemical action is not enough if it is sufficiently linked
causally, too remote from the site of treatment, or not grounded in the article
itself. See Koolage & Hall, supra note 97 (exploring challenges related to
defining chemical action, including the questions of where in the causal chain
the chemical action occurs, and how removed the chemical can be from the site
of therapeutic action).
249. See U.S. FOOD & DRUG ADMIN, ABBREVIATED APPROVAL PATHWAYS FOR
DRUG
PRODUCT:
505(B)(2)
OR
ANDA?
(2019),
https://www.fda.gov/media/130898/download
(explaining
how
“active
ingredient sameness” is evaluated).
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which had a readily characterizable and reproducible active
ingredient. Today, many drugs involve complex structures, for
which demonstrating sameness may not be feasible.250
Bioequivalence is also problematic for complex products, which
may involve unconventional methods of conveying the drug to
the site of action, for instance, drugs involving nanotechnologybased carriers or device-controlled delivery.251 Lack of an
alternative drug pathway based on “similarity” rather than
“sameness” gives competitors fewer options for developing a
competing complex drug product.
Complex drug products thus present three barriers likely to
increase prices and reduce competition: (1) high costs to develop
and approve pioneer product; (2) technological challenges to
producing follow-on competition; and (3) regulatory restrictions
to follow-on competition. Table 5 illustrates the consequences
that converge when Complex Products are classified as drugs.

250. For example, NBCDs might not contain a single, discrete active
ingredient, or it may not be feasible to show bioequivalence. See Food Drug
Cosmetic Law Reports Letter No. 2570, Food Drug Cosm. L. Rep. 839392
(C.C.H.), 2018 WL 839392, at 8–9.
251. See JAMES T. O’REILLY & KATHARINE A. VAN TASSEL, FOOD AND DRUG
ADMINISTRATION §13:131 (4th ed. 2019) (describing the “challenges of reviewing
generic versions of nonbiological complex drugs”); see also In re Restasis
(Cyclosporine Ophthalmic Emulsion) Antitrust Litig., 352 F. Supp. 3d 207
(E.D.N.Y. 2019) (deciding a motion to compel discovery on documents related to
a suit brought by buyers of a dry-eye medication); Exhibit 13, In re Restasis,
352 F. Supp. 3d 207 (E.D.N.Y. 2019) (No. 1:18-md-02819-NG-LB) (describing
how non-biological complex drugs, such as RESTASIS, require thorough
analysis to evaluate bioequivalence).
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Table 5. Consequences of Classification on Example
Medical Products

Medical
Product

An artificial
hip implant.
Small
Molecule Drug
A recombinant
human
granulocyte
colony
stimulating
factor.
A complex
mixture of
non-biological
materials that
self-assemble
into a variety
of structural
forms having
features on the
nanoscale. . .
...
primarily for
serving a
mechanical
purpose in the
human body.

Classifica
tion

Cost to
Get
Approval

Does
Current
Technology
Permit
Follow-On
Competition
Based on
ReadilyValidated,
Measurable
Physical
Properties?

Does the
Current
Legal
Regime
Permit
Follow-On
Competitio
n Based on
Similar
Properties?

Device

Low

Yes

Drug

High

Yes

No

Biologic

High

No

Yes

Yes

Example of a complex product.
The burden of approval and barriers to
competition depend on classification.

Device

Low

No

Yes
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. . . primarily
for measuring
or identifying
a condition of
the human
body.
. . . primarily
for acting as a
depot for
extended
release of
drugs.
. . . primarily
for inducing
immune
activity.
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High
No.

Drug

High

Drug

High

Complex products
classified as drugs suffer
from both technological
and legal barriers to
follow on competition.

iv. Technological Challenges of Complex Products.
Technological challenges, not regulatory issues, likely
represent the greatest barrier to Complex Product competition.
For Complex Products, it can be incredibly challenging to
scientifically prove “sameness” or other types of equivalence,
when structure and function are not yet fully understood.
Typically, those who try to bring follow-on Complex Products to
market must do substantial additional research and
development, particularly with respect to structure-function
validation, and sometimes involving additional clinical trials.252
Even though an innovator may have obtained approval for a
complex new product, it is another thing entirely for a
competitor to learn how the product’s structure, manufacture,
and function interrelate, and then produce it and obtain FDA
approval. Follow-on competitors must conduct further research
prior to seeking approval to address these concerns.253 This
252. See C. Lee Ventola, Biosimilars: Part: Proposed Regulatory Criteria for
FDA Approval, 38 PHARMACY & THERAPEUTICS 270, 270 (2013) (explaining that
“[t]he structure–function relationships of biologics are very sensitive”).
253. For example, Complex Products may involve nuances to structural
aspects or sensitive manufacturing relationships that influence therapeutic
properties. An attempted copy of a Complex Product may appear to have all the
same recognizable and obvious features, but overlooked or indecipherable
nuances may be essential to achieving the desired therapeutic effect. See Luke,
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research burden represents a significant “technological” barrier
to follow-on competition.
Secondly, there is a problem that such research efforts are
redundant. Prior to obtaining approval of a Complex Product,
the innovator likely dedicated significant resources into
researching the structural, functional, and manufacturing
tolerances of its product. This research may relate to deciphering
which minute manufacturing aspects are acceptable and which
are not, or it may relate to a way of characterizing structure that
can be used to discern equivalent versus non-equivalent versions
of the product. The results of this research are economically
valuable but often not suitable for patent protection. 254
Accordingly, such information is typically kept as a trade
secret.255 Clinical data generated by the innovator and shared
with the FDA will ultimately be made available after approval
of its product, but usable only after any period of data exclusivity

supra note 1 (describing the regulatory process for pre-ANDA Complex Generic
Products); see also Jiang, supra note 1 (describing the considerations involved
in analyzing complex generic drugs); see also U.S. FOOD & DRUG ADMIN. OFFICE
OF GENERIC DRUGS, 2019 ANNUAL REPORT: ENSURING ACCESS TO SAFE,
AFFORDABLE,
AND
EFFECTIVE
GENERIC
DRUGS
(2019),
https://www.fda.gov/media/135329/download (providing an overview of the
generic drug state of affairs); see also FED. DRUG ADMIN., GENERIC DRUG USER
FEE AMENDMENTS (GDUFA) SCIENCE AND RESEARCH PRIORITY INITIATIVES
FOR FISCAL YEAR 2020 (2020), https://www.fda.gov/media/132370/download
(listing FDA’s priority initiative regarding the acceleration of access to generic
drug products); see also Vinod Shah, Non-Biological Complex Drugs: Challenges
for Approval Standards and Opportunities!, NON-BIOLOGICAL COMPLEX DRUGS
(NBCD)
WORKING
GROUP
(Apr.
22,
2019),
https://www.fda.gov/media/125176/download
(discussing
challenges
for
approval standards of NBCDs).
254. See infra Section II(B)(ii). For example, it may be vulnerable to attack
on obviousness or anticipation grounds over the innovator’s own pre-clinical
disclosures. Such information is often developed late in the development process
while conducting detailed investigations of scale-up manufacturing and
validation. Sometimes even if a patent were obtained based on the new
information, it may be vulnerable to work around or difficult to enforce. In other
cases, the information relates to similar products, but not the approved product,
so any resulting patent would not sufficiently protect the innovator’s own
product.
255. See Kristan Lansbery, Protecting Trade Secrets in the Medical
Approval
Process,
https://www.fdli.org/2018/04/update-protecting-tradesecrets-medical-product-approval-process/ (last accessed August 15, 2020)
(discussing the value of maintaining trade secrets of medical products during
FDA approval).
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expires.256 In contrast, the information kept as a trade secret
might never be shared.
When competitors subsequently pursue follow-on products,
they must independently and redundantly develop an
understanding of the structural, functional, and manufacturing
tolerances of the product in order to reproduce a product with
the requisite sameness or therapeutic equivalence. These
development efforts must be underway well before any earlier
research will be publicly disclosed, in order to obtain generic
approval at the earliest opportunity. Moreover, each competitor
will likely keep their own results secret from each other, thus
resulting in further redundant efforts.
B. PROPOSED SOLUTION—RETHINKING CHEMICAL-BASED
STATUTORY LANGUAGE AND TECHNOLOGICAL BARRIERS TO
COMPETITION
Rethinking the chemistry-based requirements of 21 U.S.
Code § 321(h)(3) and 21 U.S.C. §355(j) will better align
regulatory burdens and incentives, reduce regulatory
uncertainty, and provide more appropriate pathways for
Complex Product competition. One possible resolution is
incentivizing disclosure of pro-competitive information in
exchange for a period of exclusivity.
First, a clearer definition of Complex Products is needed.
This Note suggests the following definition, which is couched in
terms of the technological uncertainty related to establishing
equivalence:
A Complex Product is a drug, device, biologic, or
combination product for which the critical qualities necessary for
determining equivalency of relevant follow-on products are not
predictably ascertainable using publicly known technology.
For example, Complex Products can include products that
exhibit: structural complexity in which the structural aspects
that influence safety or efficacy cannot be predictably
ascertained, characterized, or controlled using publicly known
technology; functional complexity in which the functional
properties, including physiologic properties, that influence
safety or efficacy cannot be predictably ascertained, modeled, or
controlled using publicly known technology; and operational
256. Such data exclusivity periods are statutorily prescribed and provide an
essential window for innovator profitability that delays generic entry.
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complexity in which the use or operation of the product
influences safety or efficacy in a manner which cannot be
predictably ascertained, modeled, or controlled using publicly
known technology.
i.

Redefining Chemical Action As Biochemical Action

The chemical action clause should be interpreted to provide
a non-arbitrary result, even in borderline cases. A proper
definition of “chemical action” should result in a delineation
between drugs and devices that reflects a meaningful legislative
goal, not simply an attempt to square Congress’s word choice
with current scientific understanding. In 1970, President
Richard Nixon established the Cooper Committee to report on
the need for medical device legislation, noting that devices
present different issues than drugs.257 When Congress passed
the Medical Device Amendments of 1976, it specifically
introduced a new risk-based approach to the FDA’s premarket
review.258 Devices were considered to pose different risks based
on recognizing how much control an operator had over the
therapeutic effect and any risk of harm.259 Indeed, the device
regulatory scheme is organized around general and special
controls providing a reasonable assurance of safety and efficacy.
In contrast, new drugs were considered to always require
rigorous premarket approval and clinical evaluation. When
Congress passed the Medical Device Amendments of 1976, it
introduced its risk-based approach to devices only, establishing
that devices would be treated differently than drugs and that
chemical action would distinguish devices from drugs.260 The
257. See A History of Medical Device Regulation & Oversight in the United
States,
U.S.
FOOD
&
DRUG
ADMIN.
(June
24,
2019),
https://www.fda.gov/medical-devices/overview-device-regulation/historymedical-device-regulation-oversight-united-states (noting that the committee
“[r]ecommended that any new legislation be specifically targeted to the devices
because devices present different issues than drugs”).
258. See id. (noting that the act “[c]reated a three-class, risk-based
classification system for all medical devices”).
259. See Regulatory Controls, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/medical-devices/overview-device-regulation/regulatorycontrols (last updated Mar. 27, 2018) (“Each device is assigned to one of three
regulatory classes: Class I, Class II or Class III, based on the level of control
necessary to provide reasonable assurance of its safety and effectiveness.”).
260. See id. (describing intent of amendments as to “provide reasonable
assurance of the safety and effectiveness”); See also 21 U.S.C. §201(h) (defining
a “device”).

2020]

COMPLEX PRODUCTS

531

FDA has since interpreted “chemical action” based on a purely
scientific, but overly literal, definition.261 This leads to results
that can be arbitrary, based on scientifically dated semantics,
rather than based on risk to patients.
A different statutory interpretation of chemical action
would permit the FDA more flexibility to avoid arbitrary
classification of drugs and devices. First, “chemical action within
or on the body of man or . . . dependent upon being
metabolized . . . ”262 should be interpreted as referring to the
chemical processes that provide for the complex functioning of
the body, i.e., biochemistry. Second, the statutory requirement
that a device does not “achieve its intended purposes through
chemical action,”263 reflects that chemical action is an intrinsic
quality of the article itself, and that there is a distinction
between therapeutic results that arise as a result of this intrinsic
quality, rather than by other means. Moreover, it should be clear
that Congress intended the chemical action distinction to be
consequence driven.
The following two-step inquiry, based on the abovesuggested interpretation of chemical action, should be used to
determine if a product can be a device:
1) Is the primary intended purpose achieved due to (a)
extrinsic control over the article by a human or (b) intrinsic
features of the article? If (a), the product can be a device. If (b),
continue to step 2.
2) If step 1 is (b), are the intrinsic features of the article
expected to modulate or participate in any specific biochemical
or metabolic functioning of the human or animal? If not, then the
product can be a device.
One benefit of this interpretation is that it ties classification
to expected risk of biological consequences that cannot be
predictably controlled. This two-step inquiry narrows the
concept of “chemical action” to focus specifically on the type of
chemical action occurring in humans and animals, and thus
avoids an interpretation that could apply to virtually all medical
products. The intrinsic versus extrinsic distinction serves to
identify the therapeutic function that derives from the product

261. See U.S. FOOD & DRUG ADMIN., supra note 88 at 7 (2017) (expounding
on the definition of “chemical action”).
262. 21 U.S.C. §201(h) (2011) (defining a “device”).
263. Id.
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itself, e.g., a chemical structure, rather than deriving the
therapeutic function from the skill of a user.264 Another benefit
is that this interpretation satisfactorily provides a means to
classify Complex Products and other borderline cases in a
manner that is non-arbitrary and based on expected
consequences in patients.
ii. Applying a Standard Beyond Sameness
The sameness requirement for drug follow-on products is
overly limiting: some products that are classified as drugs have
greater tolerance to structural variation than did traditional
small-molecule drugs.265 There should be alternative approval
paths for follow-on drugs when the FDA expects that such
products would likely be safe and effective despite being merely
“similar” or “substantially equivalent” to the reference product.
The follow-on drug pathway should be updated to
incorporate the “similar” pathway from biologics and the 510(k)
pathway from devices. This change could be implemented by
qualifying each new approved product according to its tolerance
to structural variation and risk. For example, an approved drug
that has different therapeutic properties when the structure is
altered should be limited to a sameness-type (ANDA) path. For
approved drugs that demonstrate that minor variations can
result in the same therapeutic effects, a similar-type
(biosimilars) path would be suitable. For approved drugs where
significant variations could be possible without effecting
therapeutic effects, for instance, surfactant-based products or

264. An alternative analysis focused on locality, singularity, and causality,
which are loosely analogous to the therapeutic effect deriving from intrinsic
properties of the article. See Koolage & Hall, supra note 94.
265. When the Hatch-Waxman Act was enacted, drugs were primarily based
on small molecule compounds. Such compounds typically had very narrow
tolerance for structural variation—even replacing a single atom or functional
group risked unexpected properties. Gerald J. Mossinghoff, Overview of the
Hatch-Waxman Act and Its Impact on the Drug Development Process, 54 FOOD
& DRUG L.J. 187, at 190 (1999) (“One major assumption underlying the HatchWaxman Act was that duplicates of pioneer drugs would be the same as the
innovator’s drug.”) See also Is Biosimilar Insulin Available?, BIOSIMILARS
RESOURCE CTR., https://www.biosimilarsresourcecenter.org/faq/biosimilarinsulin-available/ (explaining that, for historical reasons, insulin is regulated
as a drug and so biosimilar competition is not legally permitted, while at the
same time generic competition is not technologically feasible since insulin is not
a small molecule drug for which exact structural duplicates can be made by a
follow-on competitor).
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pH neutralization products, then a 510(k)-type pathway would
be suitable for follow-on competition.
Table 6. Summary of Different Rationales for Permitting
Follow-On Product Entry.
Sameness-type
Similar-type
510(k)-type
Minor variations in
Minor variations in
Significant
chemical structure
chemical structure
variations in
of an active
may be permitted
chemical structures
ingredient are not
where the product is may be permitted
permitted because
expected to produce
where such
minor variations
the same clinical
variations would not
would be expected to result.
be expected to
provide different
reduce the safety or
therapeutic effects.
functioning of the
device.
The benefits of this approach are that it would permit
additional paths for follow-on competition of drugs and conform
the regulatory framework for follow-on products across classes.
This also permits the FDA additional flexibility to determine the
appropriate, science-based restrictions on follow-on products.
iii. Incentivize Early Disclosure of Pro-Competitive
Information
Significant research is required to determine how to
separately produce Complex Products that are therapeutically
equivalent to a reference product. When a competitor pursues
approval of a generic or similar, there is a question regarding
precisely how identical or similar the Complex Product must be
in order to be therapeutically equivalent.266 Each competitor
must independently and redundantly solve this problem to the
FDA’s satisfaction before it will receive approval.267 However,
similar problem-solving efforts occur during an innovator’s
pioneer development efforts. For example, the innovator may

266. See Jiang, supra note 1, at 25 (posing the question “[h]ow similar is
equivalent?”).
267. See Shah, supra note 1, at 4 (explaining that non-biological complex
drugs “cannot be fully characterized by physicochemical analytical means” and
stating that “[a] well-controlled robust manufacturing process is fundamental
to ensure quality, safety and efficacy”).
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discover during product optimization that certain variations in
structure (such as variation in particle sizes, crystal shapes,
glycosylation patterns, or polymer-chain distribution) might
cause the product to fail while other changes result in an
equivalently functioning product. During manufacturing scaleup, the innovator may discover nuanced manufacturing details
(such as the importance of a steel tanks, a delay between process
steps, or the order excipients are added), which might influence
therapeutic functioning but for which no structural difference
can be determined. During clinical trials, the innovator might
discover that the way the product is used is influenced by
seemingly trivial features (such as the color or shape of an
inhaler influencing how deeply a patient breaths). These types
of findings can identify critical quality attributes that are
relevant to obtaining a conforming pioneer product, or they can
be relevant to understanding which minor variations will be
therapeutically equivalent. Fortunately, such discoveries
naturally arise as a normal part of preparing a pioneer new drug
for FDA approval, e.g., when studying characterization, batch
conformation, method validation, and product specifications.
Yet, the innovator has every reason to keep such insights as
confidential trade secrets and no incentive to disclose them to
the public—especially if a patent is unavailable because the
innovator’s prior disclosed product inherently embodied the
same parameters. As a result, competitors must redundantly
labor to uncover know-how that was likely previously
ascertained by the innovator.268 This represents a redundant,
cumulative waste of resources that contributes to the high cost
of health care.269
Redundant and costly development efforts can be eliminated
by incentivizing early disclosure of critical quality attributes for

268. See U.S. FOOD & DRUG ADMIN., supra note 60 at 5 (“Liposome drug
products are sensitive to changes in the manufacturing conditions . . . .
Appropriate process controls should be established during product
development. Prior knowledge can be leveraged and risk assessment techniques
can be used to identify manufacturing process parameters that potentially
affect finished product quality.”).
269. See Scott Gottlieb, M.D., Reducing the Hurdles for Complex Generic
Drug Development, U.S. FOOD & DRUG ADMIN. (Oct. 2, 2017),
https://www.fda.gov/news-events/fda-voices-perspectives-fda-leadership-andexperts/reducing-hurdles-complex-generic-drug-development (“While the FDA
doesn’t control drug pricing, our policies do affect competition in the market.
This is the nexus of our current efforts on drug pricing.”).
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therapeutic equivalence. The patent system is the primary
governmental tool for incentivizing disclosure of new and useful
technological progress.270 Yet, present patent doctrine will not
reward a party that discloses additional information about key
qualities of a previously used or disclosed product, even if those
qualities were never appreciated or are critically important for
the development of a competitive equivalent product. Several
aspects of patent doctrine prevent innovators from patenting
subsequent discoveries about features of earlier inventions, and
yet the doctrine also lends little support to competitors seeking
to make therapeutic equivalents of an innovator’s product. These
aspects of the doctrine include: (1) a prior disclosure of a species
anticipates a subsequent broader, encompassing genus; (2) an
invention is anticipated if a prior disclosure invention inherently
had the same features, even if not appreciated; (3) there is no
requirement that a patent disclosure should enable quick, lowcost copying; and (4) there is no requirement that a patent
disclosure identifies features critical for meeting FDA’s
bioequivalence requirements.

Scheme 1
A patent, with its many embodiments, can be represented
as illustrated in Scheme 1. The outer perimeter represents the
scope of the broadest disclosure. The block dot represents a lead
product, submitted to the FDA pending approval. Other

270. Rebecca S. Eisenberg, The Shifting Functional Balance of Patents and
Drug Regulation, 19 HEALTH AFF. 119, 123 (2001) (“It is awkward to meet such
[pharmaceutical] industry-specific needs for exclusivity through provisions of a
unitary patent system designed to provide innovation incentives for all
industries.”).
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products also fall within the scope of the patent’s claims. These
other products, represented by white dots, might have
equivalent, or different, functioning compared to the clinical
candidate. The written description and enablement
requirements under 35 U.S.C. §112 require that patents clearly
define the claim scope and describe how to “enable” others to
make and use the claimed invention, even if doing so would be
time-consuming,
expensive,
and
involve
reasonable
experimentation.271 There is no requirement that enablement
describe how to make an exact copy of the product that FDA
ultimately approves, or even how to make a therapeutically
equivalent product. Moreover, nothing in the patent doctrine
requires an innovator to identify which of its embodiments are
equivalent to the others, or how exactly a competitor should
optimize manufacturing to achieve matching therapeutic
equivalence.

Scheme 2
Scheme 2 illustrates how the scope of a patent disclosure
differs from the scope of possible therapeutic equivalents of a
lead product. Here, the scope of therapeutic equivalents would
be defined by FDA’s requirements for follow-on products, e.g.,
under 505(j), 510(k), or BPCI Act. The solid circle represents
patent scope, while the dashed circle represents product space
containing suitable variant products that are equivalent to the
lead product. For Complex Products, determining the metes and

271. See 35 U.S.C §112 (2012); see also U.S. PAT. & TRADEMARK OFF.,
MANUAL
OF
PATENT
EXAMINING
PROCEDURE
§2164
(2018),
https://www.uspto.gov/web/offices/pac/mpep/s2164.html [hereinafter MPEP];
see also In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988).

2020]

COMPLEX PRODUCTS

537

bounds of what exactly is therapeutically equivalent, can be far
more challenging than for conventional products. Developing
any follow-on product involves the challenges and costs of
identifying what attributes of the pioneer product affect
equivalence, and how to measure, make, and control those
attributes. For Complex Products, this technology and knowhow is either not within the reach of current science, or is not
publicly known.
After filing a patent and beginning clinical trials, an
innovator typically develops technology that identifies critical
quality attributes that can distinguish between equivalent a
non-equivalent variations of their product, i.e., that can define
the scope of FDA approvable therapeutic equivalents. For
example, the innovator would have investigated a wide variety
of structural and functional variants prior to selecting the final
lead product for clinical testing. Moreover, manufacturing
modifications likely lead to development of critical validation
and characterization methods that are useful for predicting
which batches and similar variants will have therapeutic
properties.
However, the innovator cannot necessarily obtain a patent
claiming a product defined by these critical quality attributes.
Such claims would be inherently anticipated—and thus
unpatentable—over an earlier, pre-clinical disclosure of the lead
product assuming the product had previously exhibited those
same attributes. Although the innovator is typically first to bear
the costs of identifying critical quality attributes associated with
therapeutic equivalence, the innovator has no incentive to
disclosure these critical attributes without the ability to obtain
a patent. These costs are then redundantly borne out by each
competitor who, in turn, have no incentive to disclose their
insights. Redundant development efforts would be eliminated if
the innovator had an incentive to disclose how much variation
in structure, formulation, and manufacture is permissible, as
well as the corresponding validation and characterization
methods that identify equivalent variants.
A statutory mechanism should be created that rewards
innovators with an extended period of exclusivity on their new
Complex Product in exchange for disclosing information that
enables others to predictably manufacture, identify, and obtain
approval for an ANDA-type or similar-type therapeutic
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equivalent.272 The period of extended exclusivity would be
conditioned on the sufficiency of the disclosure. A sufficiently
strong incentive may encourage the innovator to go beyond what
is needed for approval of its lead product, and to further seek
formal confirmation from the FDA that certain similars would
indeed be approvable. The integrity of the system could be
assured by permitting competitors to litigate over the sufficiency
of the disclosure.
This disclosure could take the form of a patent application
submitted to the USPTO, or it could take the form of a public
disclosure submitted to the FDA. In the form of a patent, the
patent would recite claims to “an FDA-validated therapeutic
equivalent” of the innovator’s lead product and providing critical
quality attributes that are sufficient for obtaining an approvable
equivalent.273 The FDA could facilitate such disclosures by
cooperating with the innovator to establish critical quality
attributes, and even indicate to innovators when suitable
variations of their lead product would be approvable as well.
Although permitting such patents could significantly extend
patent exclusivity on branded compositions, the accompanying
disclosure would contain enough data and know-how that any
number of competitors could readily produce an approvable
follow-on at minimal cost. If the disclosure is not adequate, the
patent will be quickly disposed of. In the form of a disclosure to
the FDA, the FDA could review it for sufficiency and then make
it public in exchange for providing the innovator with a period of
regulatory exclusivity or patent term extension.274

272. This statutory mechanism could take the form of a patent, a patent
term extension, or regulatory exclusivity.
273. If the incentive takes this form, there may need to be a rule to exempt
this claim format from inherency-type anticipation over prior disclosures of
products having the same structure, but not used as a therapeutic equivalent
and lacking an equivalency label. See 35 U.S.C §102 (2000); see also MPEP §§
2112
&
2131,
https://www.uspto.gov/web/offices/pac/mpep/s2112.html.
Enablement should require a showing of the FDA’s indication of approvability,
in contrast with the conventional standard of In re Brana since, here, the
proposed claims expressly invoke FDA action. Cf. In re Brana, 51 F.3d 1560,
1568 (Fed. Cir. 1995) (“FDA approval . . . is not a prerequisite for finding a
compound useful within the meaning of the patent laws.”). Additionally, the
patent should include an accompanying disclosure sufficient for those of
ordinary skill in the art to manufacture and obtain FDA approval of the claimed
products.
274. See 35 U.S.C. §156 (2012) (outlining requirements for an extension of
patent term).
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The benefit of this proposed system is that redundant
development efforts would be eliminated, and valuable
information is made public. Dissemination of this information
will benefit the pharmaceutical industry as a whole and advance
technological understanding of challenging areas like Complex
Products and medical nanotechnology. Although the cost of
brand drugs may enjoy a longer period of monopoly pricing, the
system would reduce overall costs to drug development, and
ultimately enable a greater number of competitors to enter the
market at once.
CONCLUSION
Complex Products involve regulatory and technological
barriers to competitor entry. Specifically, the “chemical action”
distinction of 21 U.S. Code § 321(h)(3) introduces uncertainty
into the regulatory process and can lead to arbitrary distinction
between FDA regulatory schemes. The “sameness” requirement
of 21 U.S.C. §355(j) limits follow-on drug competition to generictype products that are bioequivalent and have the same active
ingredient, route of administration, dosage form, and strength
as a previously-approved reference product. This limitation is
especially restrictive for Complex Products, for which showing
bioequivalence of the “same” active ingredient may not be
feasible. Lastly, because Complex Products involves technology
that is not yet fully understood, competitors have the burden of
identifying how structural aspects, manufacture, and
therapeutic properties interrelate. This technology and knowhow is redundantly developed by the initial innovator and
subsequent competitors, each of which presently have every
incentive to keep the information confidential from the others.
This Note suggests rethinking the chemistry-based
requirements written into the FD&C Act and further proposes a
new incentive to innovators to disclose data, tolerances, and
know-how that will lower overall costs for development in the
industry and improve scientific understanding of Complex
Products.

